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1. ZUSAMMENFASSUNG 
Die Ausbildung und der Schweregrad einer Anaphylaxie kann durch verschiedene Co-
Faktoren beeinflusst werden. Zu diesen zählen die nichtsteroidalen Antiphlogistika 
(NSAIDs), die ihre Wirkung über die Inhibition der COX entfalten. Wie NSAIDs den 
Schweregrad der Anaphylaxie beeinflussen, ist bisher nicht genau bekannt. 
Interessanterweise zeigen Anaphylaxie-Patienten mit einer NSAID-Hypersensibilität 
niedrige Konzentrationen des regulatorischen Prostaglandins E2 (PGE2). Zudem 
zeigen ASA-tolerante und –intolerante Asthma-Patienten variable anaphylaktische 
Sensitivitäten. 
Anhand der vorliegenden Arbeit sollte untersucht werden, ob sich eine PGE2-
Dysregulation auf die Ausbildung und den Schweregrad der Anaphylaxie auswirkt und 
ob diese durch genetische Prädispositionen gefördert werden kann.  
Dazu wurden zunächst die PGE2 Konzentration im Serum von ANA-Patienten und 
gesunden Individuen gemessen. ANA-Patienten zeigten reduzierte PGE2 Level, die 
invers mit dem Schweregrad der ANA korrelierten. Unterstützend weisen zwei in der 
Allergieforschung häufig verwendete Mauslinien, Balb/c und C57BL/6, 
unterschiedliche PGE2 Level auf, die wiederum invers mit dem ANA-Schweregrad 
korrelierten. Eine Stabilisierung der PGE2 Konzentration mittels eines 
pharmakologischen Inhibitors der Hydroxyprostaglandin-Dehydrogenase (15-PGDH-I) 
in vivo führte zu einer Verbesserung des ANA Schweregrades. Um in diesem 
Zusammenhang den Einfluss von ASA und PGE2 besser zu verstehen, wurde das 
Model der systemisch passiven ANA im Mausmodel eingesetzt. ASA verschlimmerte 
den Schweregrad der ANA durch die Inhibition der COX1/2. PGE2 konnte diese 
Verschlimmerung über die EP Rezeptoren 2, 3 und 4 reduzieren. Um die 
zugrundeliegenden Mechanismen der Wirkweise von exogenem PGE2 und EP-
Agonisten besser zu verstehen, wurden diese Zusammenhänge in murinen und 
humanen Mastzellen untersucht. PGE2 reduzierte die Schwere der ANA durch 
Inhibition der Mastzell-Aktivität in diesem System über die Rezeptoren EP2 und EP4. 
Anhand der vorliegenden Arbeit konnte gezeigt werden, dass bereits homöostatische 
PGE2 Konzentrationen die Aktivität der Mastzelle verändern und vor einer schweren 
ANA schützen. Zudem kann der Grad der ANA und der Einfluss des PGE2 auf die 
Mastzellantwort durch genetische Prädisposition beeinflusst werden. Die 
pharmakologische Stabilisierung des PGE2 könnte daher eine vielversprechende, 
therapeutische wie auch vorbeugende Strategie zur Behandlung risikoreicher ANA- 
Patienten sein. 
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2. SUMMARY  
The clinical outcome of anaphylaxis (ANA) can be affected by several co-factors. Non-
steroidal anti-inflammatory drugs (NSAIDs) are well-known co-factors of ANA acting 
via COX-inhibition. The NSAIDs-mediated mechanisms altering the severity of ANA 
are not well-defined. It is reported that patients of ASA (NSAID)-hypersensitivity show 
low levels of the regulatory prostaglandin E2 (PGE2). Moreover, the effectiveness of 
PGE2 administration in such patients suggests a critical role of PGE2 in ASA 
hypersensitivity. In addition, patients of ASA-tolerant and ASA-intolerant asthma show 
variable ANA sensitivities suggesting a role of genetic variation in susceptibility. 
The aim of this thesis was to study whether and how PGE2 dysregulation predisposes 
to ANA and whether genetic pre-dispositions affect the PGE2 system and therefore 
ANA susceptibility. 
First, sera from ANA patients and healthy individuals were analyzed for PGE2 levels. 
ANA patients were characterized by reduced PGE2 levels which inversely correlated 
with the severity of ANA. This disparity was confirmed by differential PGE2 levels 
between Balb/c and BL/6 strains, two genetic mouse strains frequently employed in 
allergy research. PGE2 levels in these mice were again inversely related with the 
severity of ANA. Results were confirmed by in vivo PGE2 stabilization using 15-
hydroxyprostaglandin dehydrogenase inhibitor (15-PGDH-I). Pharmacological PGE2 
stabilization ameliorated ANA severity in mice. A passive systemic ANA (PSA) model 
was applied to study the impact of ASA on ANA severity and the role of PGE2 in this 
context. ASA aggravated ANA by inhibiting COX-1/COX-2, while PGE2 reduced the 
aggravation through EP receptors 2, 3 and 4. To delineate the underlying mechanisms, 
murine and human mast cells were used to study the impact of exogenous PGE2 and 
EP agonists. PGE2 attenuated ANA severity by inhibiting MC activation through EP2 
and EP4 receptors and interfering with MC signaling.  
In summary, this thesis demonstrates that homeostatic levels of PGE2 modulate MC 
activation and protect against ANA severity. The impact of PGE2 on MC responses 
and ANA susceptibility is governed by genetic variation. Pharmacological stabilization 
of PGE2 may prove to be a therapeutic or preventive strategy in the management of 
high-risk ANA patients. 
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3. INTRODUCTION 
 
3.1 Type I Allergy 
A type I allergic reaction is based on a mast cell (MC) and Immunoglobulin E (IgE)-
dependent hypersensitivity towards foreign proteins known as allergens.(1) Allergic or 
hypersensitivity reactions are classified into four types (Type I-IV) by Coombs and Gell. 
(2) Allergy, the most common type of hypersensitivity is often equated with type I 
hypersensitivity reactions or immediate hypersensitivity mediated by IgE antibodies. It 
manifests in the form of urticaria, seasonal allergy, asthma, food allergy or anaphylaxis 
(ANA). (3) The latter one is the most severe manifestation(4) of an allergic reaction. 
When the allergen is first encountered, B-cells are stimulated by CD4+ TH2 (T-helper 
2) cells to produce IgE antibodies specific against the allergen.(5-9) During sensitization, 
specific IgE antibodies bind to IgE (FcεRI) receptors on the surface of tissue MCs and 
blood basophils. A subsequent exposure to similar allergen leads to the cross-linking 
of bound IgE on the surface of sensitized cells and results in the release of pro-
inflammatory substances (section 1.2.2) which mediate the allergic symptoms.(1, 10) 
The prevalence of allergic diseases in most industrialized countries has increased 
dramatically in the past 50 years affecting 20-30% of the populations.(11, 12) 
 
3.2 Mast Cells 
MCs are cells of the hematopoietic lineage which originate from pluripotent precursor 
cells of the bone marrow. The discovery of IgE-mediated release of histamine from 
sensitized tissue MCs (13) led to the recognition of MCs as effector cells of Type I 
hypersensitivity. Antigen-dependent activation of tissue MCs bound to specific IgE on 
their surface and the release of biologically active mediators is the central event in 
acute allergic and anaphylactic reactions. (14, 15)  
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Figure 1: The Mast Cell. Mast cells are granulated cells with several receptors on their surface, the 
most important ones being FcεRI, CD117 and FcγR and their ligands IgE, SCF and IgG respectively are 
the major activators of mast cells. Mast cells can be activated by a multitude of stimuli and there are 
many modes of mast cell response. Responses to activation include the release of pre-formed mediators 
stored within granules and the synthesis and release of new products. 
 
MCs arise from CD13+CD34+CD117+ hematopoietic progenitors in the bone marrow 
(16), but mature locally, often residing near surfaces exposed to allergens. The major 
factors for MC growth and development include interleukin 3 (IL-3), stem-cell factor 
(ligand for the receptor tyrosine kinase Kit) and TH2-associated cytokines such as IL-
4 and IL-9. MCs possess several receptors on their surface for different ligands most 
importantly CD117 for SCF and the high-affinity FcɛRI, for IgE (17) (Fig.1). The 
manifestations of MC reactions are considered to be a consequence of the release of 
pro-inflammatory mediators following antigen-induced aggregation of IgE-bound FcεRI 
receptor.(10, 18-20) 
MCs have a widespread tissue distribution and are predominantly found at the 
interface between the host and the external environment such as respiratory mucosa, 
skin and gastrointestinal tract.(17) They do not represent a homogenous population. 
Their differentiation and maturation is influenced by the microenvironment, resulting in 
morphological, biochemical and functional differences.(21) Rodent MCs subtypes can 
be divided based on their tissue distribution into two types: connective tissue mast cells 
(CTMCs) in the skin and peritoneal cavity and mucosal mast cells (MMCs) in the 
intestinal propria.(22-24) These subtypes of MCs vary in their size, histamine content, 
proteoglycan and neutral protease content which determine their staining 
characteristics.(25, 26) They show differences in function, including variable 
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responsiveness to different substances.(27) Human MCs (HuMCs) in the skin, lung and 
small intestine are classified based on the protease composition of their secretory 
granules into two types: connective tissue MCs (MCTC) cells containing tryptase, 
cathepsin G and carboxypeptidase; mucosal MC (MCT) containing only tryptase.(28, 29) 
Human and rodent MCs show a lot of heterogeneities like their dependence on growth 
factors and the contents of their secretory granules.(30) 
 
3.2.1 Mast cell signaling pathway 
MCs play a role in both innate and adaptive immune responses. (31, 32) Antigen-
dependent MC activation takes place classically by cross-linking of the FcεRI receptor. 
(10, 33) FcεRI is a tetrameric receptor that comprises an α-chain, responsible for binding 
IgE, a β-chain and a disulphide linked γ-chain homodimer, responsible for initiating 
signaling. (34, 35) FcεRI-aggregation induces a cascade of intracellular signaling events 
(Fig. 2), which requires the translocation of FcεRI to lipid rafts within the plasma 
membrane. (36)  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Mast Cell Signaling Pathway. The activation of MCs following the allergen mediated cross-
linking of FcεRI receptor on MCs involves the phosphorylation of immunoreceptor tyrosine-based 
activation motifs (ITAMs) through Lyn/Fyn followed by a cascade of tyrosine kinase phosphorylation of 
various proteins and the recruitment of different adaptor proteins. This cascade leads to the activation 
of phospholipase C (PLC) through this complex or through phosphoinositide 3-kinase (PI3K) which 
induces Ca+2 mobilization and degranulation. Cytokine production is regulated by several transcription 
factors. This illustration is based on the reference (37). 
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In a primary pathway, the signaling FcεRI β- and γ-chains are tyrosine phosphorylated 
by the action of the Src kinase Lyn, which is constitutively activated within the lipid 
rafts. (38) The phosphorylation sites within the β and γ chains contain immunoreceptor 
tyrosine-based activation motifs (ITAMS) which provide docking sites for the Src 
homology 2 (SH2) domains of associated signaling molecules.(39) The phosphorylated 
ITAMs of the γ-chains recruit the tyrosine kinase Syk, which phosphorylates 
downstream substrates after its phosphorylation including the adaptor transmembrane 
molecule linker for activation of T cells (LAT).(35, 40) The multiple tyrosines 
phosphorylated on LAT allow the recruitment of several signaling molecules like 
growth-factor-receptor-bound protein 2 (GRB2)-related adaptor protein (GADS), SH2-
domain-containing leukocyte protein of 76 kDa (SLP76), VAV and the formation of a 
receptor-signaling complex (41). This is followed by the activation of phospholipase Cγ1 
(PLCγ1) and phospholipase Cγ2 (PLCγ2) (42) via the cytosolic adapter molecules GADS 
and SLP76.(43) PLC catalyzes the hydrolysis of phosphatidylinositol (4,5)- bis 
phosphate (PIP2) forming inositol (1,4,5)-triphosphate (IP3) and diacylglycerol (DAG) 
(44) which liberate Ca2+ from the endoplasmic reticulum and induce the activation of 
protein kinase C (PKC) respectively.(45) PLCγ activation occurs through this complex 
and through phosphoinositide 3-kinase (PI3K)-mediated membrane recruitment of 
bruton’s tyrosine kinase (BTK) and phosphorylation of PLC by BTK. (46)  
Another complementary pathway (Fig. 2), involves the activation of tyrosine kinase Fyn 
and Syk inducing a signaling complex with VAV, GRB2, GRB2-associated binding 
protein 2 (GAB2) and PI3K, organized by non T-cell activation linker (NTAL)/linker for 
activation of B cells (LAB). (47) PI3K catalyzes the phosphorylation of PIP2 to form 
PIP3.This molecular configuration allows these molecules to be recruited into the 
receptor-signaling complex. PI3K activation leads to the membrane recruitment of 3-
phosphoinositide-dependent protein kinase 1 (PDK1), which activates PKCδ, 
ultimately leading to degranulation. Sphingosine kinases (SPHKs) can be activated by 
phospholipase D (PLD), Lyn or Fyn. SPHK activation regulates Ca+2 release and drives 
PKC and nuclear factor kappa-light-chain-enhancer of activated B-Cells (NFκB) 
activation, degranulation, eicosanoid production and cytokine synthesis. (48-51) GRB2 
and son-of-sevenless homologue (SOS) are associated with both the primary and 
complementary pathways and activate RAS followed by extracellular-signal-related 
kinase (ERK) mitogen-activated protein kinase (MAPK) cascade and eicosanoid 
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production by activation of phospholipase A2 (PLA2). (52) Cytokine expression is 
regulated by various transcription factors (53) and by PI3K, PKC, Ca+2 and the 
downstream activation of other transcription factors such as NFκB and nuclear factor 
of activated T-Cells (NFAT). (53, 54) 
 
3.2.2 Mast cell mediators 
The activation of MCs results in the release of various pro-inflammatory mediators (Fig. 
3) which fall into three categories:  
1) Pre-formed mediators (21) like histamine, -hexosaminidase (-hex), serotonin 
(mainly produced by MCs from mouse and rat) (55) or proteases (tryptase, chymase), 
stored in the cytoplasmic granules. 
 2) De novo produced lipid mediators(21) like Cys-leukotrienes (Cys-LTs) and 
prostaglandins (PGs), which are formed from arachidonic acid. PGD2 is released in 
large quantities from MCs, while the leukotriene predominantly produced is LTC4 
(Leukotriene C4), which is metabolized to LTD4 (Leukotriene D4), and LTE4 
(Leukotriene E4). (56) 
 3) Cytokines, chemokines and growth factors. (21) 
While the first two classes of mediators are released within minutes of antigen contact, 
cytokines and chemokines are released within 1-4 h of MC activation.(17, 56, 57) The 
inflammatory factors increase vascular permeability leading to vasodilation, 
angioedema and urticaria. (10, 58, 59) In addition, they can cause bronchoconstriction and 
hypotension, leading to anaphylactic shock in the worst case. (10, 58, 59)  
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Figure 3: Murine and human MC (HuMC) mediators. Shown are the major MC mediators released 
on IgE-mediated cell activation. This illustration is based on the references (56, 57, 60). TNF -α, tumor 
necrosis factor; IL, interleukin. 
 
MCs differ based on species and their location in the body. (57) Their mediator profile 
also varies. For example the pre-formed mediator serotonin is produced in large 
quantities by murine MCs whereas HuMCs produce serotonin only in small 
concentrations.(55) There are also differences regarding tryptase and chymase 
between MCs from both species. Murine MCs produce a number of tryptases and 
chymases (mMCP-1 to mMCP-14) (57), whereas HuMCs produce only four tryptases 
(α-,β-,γ-,δ-tryptases) and one chymase (α-chymase). (61) Human and murine MCs also 
vary regarding their secretion of cytokines like IL-4, which is formed only by murine 
MCs under physiological conditions. (56, 57, 62) 
 
3.3 Anaphylaxis 
ANA is an acute, potentially life-threatening, systemic hypersensitivity reaction, 
characterized by the release of mediators from MCs and other inflammatory cells which 
lead to a rapid onset of respiratory, cutaneous, gastrointestinal and cardiovascular 
symptoms. (63-65)  
The term anaphylaxis was originally coined by Charles Richet and Paul Portier in 1902. 
In their experiments with immunized dogs with actinia extracts (66) they observed the 
sudden onset of death instead of expected prophylaxis generating the term 
‘anaphylaxis’. For this discovery Richet was awarded with the Nobel Prize in 1913. An 
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important breakthrough to the understanding of the pathophysiology of ANA was the 
data from Dale and Laidlaw. They demonstrated that histamine induced similar 
symptoms to ANA. (67) In the following years, it was observed that similar symptoms 
can be elicited in animals without the involvement of the immune system as well as 
through the direct injection of histamine. Such reactions were termed as ‘anaphylactoid 
reactions’. (68) At the beginning of the 21st century, the nomenclature task forces of the 
European Academy of Allergy and Clinical Immunology (EAACI) and the World Allergy 
Organization (WAO), defined ‘anaphylaxis’ on the basis of clinical symptoms 
independent of the pathomechanism causing the reaction.(65) ANA describes a 
syndrome of clinical symptoms involving several organ systems with variable 
intensities. There are different severity systems used to classify the intensity of this 
reaction as proposed by Mueller(69) or Ring and Messmer (70) which are most commonly 
used. 
 
3.3.1 IgE-dependent anaphylaxis 
IgE antibodies play a significant role in conferring immunogenic specificity to effector 
cell activation in allergic reactions (section 1.1).(10, 14, 71) IgE is often increased in large 
quantities in patients suffering from allergic diseases (10, 72). The effector cells of ANA, 
MCs, blood basophils, neutrophils, eosinophils, monocytes, dendritic cells and 
platelets express the high affinity receptor for IgE, FcεRI, on their surface.(73) 
Classically, ANA is induced when cells are exposed to a bi- or multi-valent allergen, by 
crosslinking of the FcεRI receptor-bound IgE. Crosslinking of IgE and its receptor 
induces a signaling cascade (Fig. 2) that induces activation of MCs or basophils. This 
results in the release of pre-formed mediators such as histamine, serotonin, cytokines, 
proteases, along with de novo synthesis of additional cytokines and lipid mediators 
such as platelet-activating factor (PAF), PGs, and LTs. (10, 73) Passive immunization 
studies including naive mice sensitized by transfer of antigen-specific IgE followed by 
exposure to that antigen, support the importance of IgE and MCs in antigen-induced 
anaphylactic shock. (74-76) In both passive and active immunization studies, the IgE-
mediated anaphylactic reactions are completely abolished in mice with genetic or 
antibody elimination of IgE, the FcεRI receptor (75), or MCs (77-79), pointing to the 
importance of IgE-mediated MC activation in these ANA models. 
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3.3.2 IgE-independent anaphylaxis 
In mice, IgG antibodies are also known to induce passive systemic anaphylaxis (PSA) 
similar to an IgE-dependent reaction. Studies in which mice were actively immunized 
with an antigen followed by exposure to the same antigen, have demonstrated ANA in 
the absence of classical IgE/FcεRI/MC pathway. These reactions were mediated by 
mechanisms involving IgG instead of IgE. (58, 80-83) The existence of IgE-independent 
ANA in actively immunized mice was clearly demonstrated by studies in IgE- or 
FcγRIα-deficient mice but not in mice lacking stimulatory FcRγ receptors. Suppression 
or lack of ANA in mice was seen in mice lacking function of one or more mouse FcRγ 
receptors. (84-87)  
Studies of murine IgG-mediated ANA in actively immunized mice identified PAF rather 
than histamine as the most important mediator and monocytes/macrophages, 
basophils or neutrophils as the critical cell types.(81, 82, 84) These cell types express 
FcRγIII and FcγRIV in mice, and are capable of producing PAF in response to 
appropriate stimuli.(82, 88, 89) Several clinical observations support the importance of 
IgG-mediated ANA in human subjects (90-93) particularly in the presence of relatively 
high titers of specific IgG antibody and large quantities of known antigen. As 
demonstrated in mice, IgG-mediated ANA requires a larger dose of antigen than IgE-
mediated ANA. (94) 
 
3.3.3 Complement-mediated anaphylaxis 
Studies using mice have shown that small peptides, C3a and C5a, derived from C3 
and C5 respectively, known as anaphylatoxins, can activate MCs and other myeloid 
cells. (95) An activation of the complement cascade occurs in response to many stimuli, 
and leads to generation of small peptides, which are potent inflammatory mediators. 
(96) There is plenty of evidence indicating that anaphylatoxins might be involved in ANA. 
The production of C3a and C5a has been reported in human ANA. (97, 98) The injection 
of low doses of small peptides into the skin of healthy subjects led to wheal and flare 
reactions. (99-102) In addition, another study has shown the correlation between blood 
levels of small peptides and the severity of ANA in humans. (98) Several transgenic 
mice models suggest that the effect of complement components on ANA may be 
largely redundant and depend on the specific model used. (103-105) 
 
25 
3.3.4 Co-factors of anaphylaxis 
The mechanisms involved in anaphylactic reactions are complex and implicate various 
pathways. Some of these mechanisms may be key to the development of a reaction, 
while others may only modify its severity. Clinical manifestations of ANA are 
heterogeneous with signs and symptoms varying across patients. Presentation and 
severity can be affected by factors that are independent of the triggering allergen but 
modulate occurrence, severity and the course of a reaction. This has led to the concept 
of co- or augmenting factors. Around 40% of severe anaphylactic reactions have been 
reported to be influenced by such extrinsic factors. (106-109) Studies suggest two major 
mechanisms of cofactor-induced modulation of ANA: an increased bioavailability of the 
allergen and a decreased activation threshold on the cellular level (Fig. 4).(106) 
Exercise, vulnerability to psychological burden, and drugs like non-steroidal anti-
inflammatory drugs (NSAIDs) are major extrinsic factors. Intrinsic factors such as 
higher age, male sex and concomitant mastocytosis may also facilitate a reaction or 
aggravate its outcome. (106-108) Other factors like alcohol, infectious diseases and 
estrogens are also considered as important co-factors. (108, 110, 111) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: ‘Threshold dose’ model of cofactor‐dependent anaphylaxis. High allergen doses induce 
strong ANA, while low allergen doses induce subclinical allergic reaction but no ANA. In contrast, low 
‘subthreshold’ allergen doses in combination with cofactors trigger strong ANA. This illustration is based 
on the reference (106). 
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3.3.5 NSAIDs as co-factors of anaphylaxis 
NSAIDs are a well-known group of augmentation factors of ANA. The first report of a 
life threatening hypersensitivity reaction upon ingestion of peanuts in combination with 
aspirin was published in 1984.  (112) Epidemiological data suggests that NSAIDs act as 
a trigger in 1.2-4.7% of all reported anaphylactic cases. (106) They have been reported 
to be present in up to 22% of cases of food-induced severe ANA. (113) Other reports 
have shown NSAIDs in 58% of co-factor induced food-related ANA reactions in the 
Mediterranean area (114) and in around 33% of cases in lipid transfer protein (LTP)- 
induced ANA. (115)  
Studies have shown that the augmenting effect of NSAIDs in food allergic reactions 
may be related to the blockade of COX pathway and the decreased synthesis of 
PGs.(116-119) It is very well known that PGs play an important role in maintaining 
homeostasis (120, 121) (section 1.4) including the defense and repair of gastrointestinal 
tissues. NSAIDs inhibit PGs, disposing gastrointestinal tissues to injury and less 
capacity to retrieve mucosa function.(122) NSAIDs especially acetyl salicylic acid (ASA) 
is also known to cause hypersensitivity reactions known as NSAID-exacerbated 
respiratory disease (NERD) or ASA-induced asthma (AIA). These hypersensitivities 
are characterized by respiratory symptoms such as bronchospasms, acute asthma 
exacerbation (lower airway), and severe asthma morbidity. (123, 124)  
 
3.4 Cyclooxygenases and Prostaglandins 
Upon activation, MCs release arachidonic acid from cell membrane phospholipids by 
the action of PLA2 and PLC (Fig. 5). (125) Arachidonic acid is in turn converted into 
Prostaglandin G2 (PGG2) and Prostaglandin H2 (PGH2) by the action of an enzyme 
called prostaglandin endoperoxide synthase, fatty acid cyclooxygenase, prostaglandin 
H synthase (PGHS) or most commonly, cyclooxygenase or COX.(126) There are two 
isoforms of COX- , a constitutive COX-1 and an inducible COX-2, which differ in their 
regulation of expression and tissue distribution. COX-1 is responsible for the 
physiological production of PGs in the stomach, kidney, ovaries and platelets, whereas 
COX-2 is the inducible enzyme responsible for the pathological production of PGs in 
various diseases.(127) Further enzymatic conversion of PGH2 by terminal prostanoid 
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synthases (126) and various isomerases leads to the formation of PGE2, PGD2, PGI2, 
PGF2a and the related thromboxane A2. (128) 
Figure 5: Prostaglandins synthesis and receptors. Arachidonic acid is released from the membrane 
phospholipids and converted to prostaglandin H2 (PGH2) by cyclooxygenases-1/2 (COX-1 and COX-2). 
COX activity is inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) therefore reducing the 
synthesis of prostaglandins. Prostaglandins act via their specific receptors. This illustration is based on 
the reference (129). 
Prostaglandins are 20-carbon fatty acid derivatives of mainly arachidonic acid with 
important roles in homeostasis and inflammation. They are produced by almost every 
cell of the body.(120, 130, 131) They are not stored by cells rather synthesized either 
constitutively or in response to cell-specific trauma, stimuli or signaling molecules. (131) 
PGs mediate pain and fever (132), and COX-inhibitors i.e. NSAIDs are the most 
commonly used anti-inflammatory, and anti-pyretic drugs. They act by inhibiting the 
activity of COX enzymes (COX-1 and COX-2) and the consequent reduction in 
prostaglandin levels.(133)  
As mentioned earlier, NSAIDs/ASA represent a prominent group among the co-factors 
of ANA. (4, 106) A large body of evidence supports a close link between the inhibition of 
COX and the manifestation of an allergy/hypersensitivity (table 1).  
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Model used Results Publication 
Allergic airway disease mouse 
model (COX deficient/ WT 
mice) 
COX protects from lung 
inflammation after allergen 
challenge. COX-1 has greater 
effect than COX-2. 
Gavett et al. 1999 (134) 
Allergic airway disease mouse 
model 
COX inhibitors increase AHR. 
COX-1 is dominant over COX-2. 
Peebles et. al 2000 (135) 
Allergic airway disease mouse 
model (COX-1/-2 deficient/WT 
mice) 
COX-2 reduces 
bronchoconstriction 
Carey et. al 2003 (136) 
Allergic airway disease mouse 
model (COX-2 deficient/WT 
mice) 
Reduced PGE2 associated with 
COX-2 deficiency 
Nakata et. al 2005 (137) 
Allergic pleurisy mouse model  PGE2 downregulates allergic 
response and mediates 
subsequent hypo 
responsiveness 
Bandeira-Melo et. al 1996 (138) 
Table 1: Decreased COX activity associated with increased allergic symptoms. Reports showing 
the importance of COX in the manifestation of allergy/hypersensitivity. COX, cyclooxygenase; PGE2, 
Prostaglandin E2. 
 
3.5 Prostaglandin E2 
PGE2 is one of the most abundant PG subtypes produced by almost all cells and 
tissues throughout the body with a complex mode of action and versatile biological 
activities. (139-141) Under physiological conditions, PGE2 is an important mediator of 
several biological functions such as the regulation of immune responses, blood 
pressure, gastrointestinal integrity, kidney function, skin homeostasis and fertility. (121, 
130, 131, 142) PGE2 has a wide range of (sometimes opposing) biological effects both in 
physiology and pathology. (130, 140, 143) Knockout studies in mice show that PGE2 can 
exert both pro-inflammatory and anti-inflammatory responses. (144-147) Diversity and 
complexity related to PGE2 is created at different levels: 1) PGE2 synthesis, there are 
three specific PGE2 synthases (PGES)- cytosolic PGES (cPGES; constitutively 
expressed) and microsomal PGES (mPGES1/2;inducibly expressed). (126) 2) The 
existence of four PGE2 receptors, named E-prostanoid/s (EP/s) 1 to 4 (Fig. 6).  
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The PGE2 receptors are members of the G-protein coupled receptor (GPCR) family 
with distinct downstream effectors.(130) EP1 receptors are coupled to Gαq/p and 
mediate signaling by activation of PLC which ultimately results in the increase of 
intracellular Ca2+.(140) EP2 and EP4 receptors are coupled to the stimulatory Gαs and 
mediate the stimulation of cAMP/PKA signaling. (148) The EP3 receptor is unique and 
has different isoforms (3 in mice and 12 in humans), which are coupled to either the 
inhibitory Gi/Gq or Gs proteins thereby mediating different effects. (149, 150) Diverse 
factors regulate the outcome of EP receptor signaling. The structural, pharmacological 
and functional differences between the receptors influence the biological effects of 
PGE2. (143) More importantly, the characteristic pattern of expression as well as their 
relative ratios in different cells/tissues can cause diversity in the functions of PGE2. (151-
154) Despite the pro-inflammatory functions of PGE2, it has a protective function in 
allergic diseases. (155, 156) 
Figure 6: PGE2 signaling pathways (145): PGE2 acts via four G-protein coupled receptors: E-
prostaglandin (EP) 1-4. EP1 receptor is Gq-coupled and its activation increases Ca+2 mobilization 
through Ca+2 channels via phospholipase C (PLC). EP3 receptor is Gi-coupled and increases 
intracellular Ca+2 through PLC activation and/or blocks cAMP production via adenylate cyclase (AC). 
EP2 and EP4 receptors are Gs coupled and stimulate cAMP production via AC. 
 
3.5.1 Prostaglandin E2 and Anaphylaxis 
PGE2 was originally regarded in the immune system as a contributor to the progression 
of inflammatory diseases. (131) However, the discovery of its bronchodilator property 
associated with asthma, first revealed its anti-inflammatory role. (157) Picado et al. (158) 
and Sczecklic et al. (159) first identified that nasal polyps and fibroblasts obtained from 
asthmatic patients express less COX-2/PGE2 than airway cells from healthy donors. 
These reports proposed that the lack of PGE2 production in asthmatics may partially 
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explain the onset of symptoms. These observations formed the pioneer attempts to 
better understand the protective role of PGE2.  
The well-known capacity of NSAIDs/COX-inhibitors to trigger asthma (160), and the 
occurrence of ASA hypersensitivity phenomena (161-163) provide major evidence for the 
protective role of COX/PGE2 in the elicitation of allergic symptoms. (135, 164-166) The 
underlying causes are uncertain but reports suggest that inhibition of the COX pathway 
by NSAIDs/ASA leads to an increase in the metabolites of the lipoxygenase pathway. 
(162, 167) However, this theory has been contradicted by others. (168, 169) It is believed that 
lack of PGE2 is responsible for the precipitation of allergic symptoms both in the lung 
and the skin. Studies have reported low levels of PGE2 in patients with AIA compared 
to patients with ASA tolerant asthma (ATA) or healthy subjects. (170, 171) In addition, 
impaired production of PGE2 and low COX expression has been reported in cells from 
patients of ASA-exacerbated respiratory disease (AERD). (159, 170, 172) Reduction of 
PGE2, therefore, is termed as a characteristic of ASA-induced hypersensitivity. Another 
evidence comes from reduced EP2 expression levels in AIA (173) and a genetic variant 
of the EP4 gene (resulting in reduced expression) in connection with AIU. (174) The 
significance of PGE2 as a critical component in ASA hypersensitivity is also supported 
by its (and synthetic analogues) effectiveness in ASA-induced bronchoconstriction. 
(175-177) 
Strong evidence that PGE2 may inhibit allergic inflammation is provided by animal 
studies using pharmacological and genetic methods to limit prostaglandin synthesis in 
a model of ovalbumin (OVA) induced lung allergy (135, 178). Mice lacking EP3 receptors 
were reported to have increased allergic inflammation suggesting that a loss of PGE2 
is at least partly responsible for the enhanced inflammation in COX-deficient and 
NSAID treated animals. (166) PGE2 has also been shown to limit inflammation in animal 
models of asthma. (179-181) 
 
3.5.2 Prostaglandin E2 and Mast Cells 
MC activation is a key event in the allergic inflammatory response. The expression of 
PGE2 receptors by MCs (182, 183), combined with the close proximity to PGE2-secreting 
cells, such as fibroblasts (184) and macrophages (185), suggest MCs as potential targets 
for immunoregulation by PGE2. (153) Reports suggest that one possible explanation for 
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PGE2’s range of functions in allergies and asthma is its direct interaction with the 
different EP receptors on the surface of MCs. (151-154) The evidence comes from the 
involvement of MCs in the regulation of asthma (10), the ability of PGE2 to limit MC 
degranulation (186) and the differential expression of PGE2 receptors on subsets of 
human and murine MCs. (187)  
MCs are known to show a wide range of responses towards PGE2, but the literature 
does not homogenously point in one direction. PGE2 has been reported to show 
potentiation of MC release in immunologically stimulated bone-marrow-derived MCs 
(BMMCs), peritoneal- derived MCs, human LAD2 cells and some cord-blood derived 
HuMCs including histamine/β-Hex, IL-6 and GM-CSF production. (153, 187-190) On the 
contrary, there are also reports including the same and other MC systems suggesting 
that PGE2 may exert a dampening effect, e.g.: PGE2-treated HuMC derived from cord 
blood (152), from blood progenitors (187, 190) or human lung MCs (154), display attenuated 
release of TNF-α, histamine/ β-Hex and Cys-LTs. Additionally, diminished releasability 
has also been shown by C57 MC line treated with PGE2. (187)  
This apparent dichotomy has been related to the multiple EP receptors on the surface 
of MCs. (151-154) MCs from different sites such as lung, peritoneum or blood-derived (151, 
152, 154), different species (151-153) or different human donors (189) express varied levels of 
EP receptors and have shown different responses towards PGE2. The comparison of 
different human and murine MCs, revealed that EP2 and EP3 receptors have dominant 
expression whereas EP4 is lowly expressed. (187) The expression of EP1 is virtually 
null. Only when EP2 is scarcely expressed in a given population, EP4 might be of 
biological importance.(191) A study by Serra-Pages et al. showed that the relative 
expression of EP2:EP3 is central in determining the cell response towards PGE2. (187) 
However, it contrasted with another study suggesting that the heterogeneity of 
responses to PGE2 result from differential coupling of EP receptors to signaling 
components rather than different EP2/3 ratios. (189) EP2 receptor has been shown to 
inhibit lung HuMC degranulation (151, 154), TNF and eicosanoid production in cord-blood 
derived HuMCs (152), Fyn-mediated signaling and hence FcɛRI-mediated degranulation 
in PDMCs. (187) In contrast, the EP3 receptor can enhance antigen-mediated human 
and murine MC responses. (192, 193) The importance of EP4 receptor for transducing 
inhibitory actions of PGE2 on MCs came into light only recently. (191) Overall, the 
literature shows a lot of paradox around the impact of PGE2 on MCs.  
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4. AIMS AND OBJECTIVES 
Prostaglandin E2 is a multifunctional prostanoid with an important role in immune 
regulation. A number of studies have suggested a protective role of COX and PGE2 in the 
precipitation of allergic symptoms. Accordingly, reduced production of PGE2 was found 
to be a characteristic of ASA (COX-inhibitor)-induced hypersensitivity. The aim of the 
present thesis was to study the PGE2 system in association with ANA susceptibility 
and aggravation, and to delineate the underlying mechanisms. 
The objectives of the study were: 
1. To study the human PGE2 system in ANA patients by comparison with healthy 
subjects. 
2. To characterize the murine PGE2 system by comparing two mouse strains 
frequently employed in allergy research for their susceptibility towards ANA and 
relation to PGE2 deregulation. 
3. To study the impact of ASA/COX-inhibitors on ANA severity and the role of 
PGE2 using an in vivo model of ANA.  
4. To pin down the biochemical events by which the PGE2 pathway impacts MC 
responses in vivo and in vitro and to identify the molecular partners especially 
EP subset (s) involved. 
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5. MATERIALS AND METHODS 
 
5.1 Materials 
 
5.1.1 Cell lines 
Cell line Provider 
HEK293 Cell Lines Service, GmbH, D 
 
5.1.2 DNA clones and vectors 
Clone/Vector Provider 
pTCN empty vector transOMIC technologies, inc., USA 
pTCN-PTGER2 (Homo sapiens) transOMIC technologies, inc., USA 
pTCN-PTGER3 (Homo sapiens) transOMIC technologies, inc., USA 
pTCN-PTGER4 (Homo sapiens) transOMIC technologies, inc., USA 
 
5.1.3 Reagents and Chemicals 
Reagent/Chemical Manufacturer 
3,3’,5,5’-Tetramethylbenzidin (TMB) Sigma Aldrich, D 
15-PGDH inhibitor, SW033291 Cayman Chemicals, D 
100 bp DNA ladder New England Biolabs GmbH, D 
α-Monothioglycerol (α-MTG) Sigma Aldrich, D 
β-Mercaptoethanol Sigma Aldrich, D 
Acrylamide Carl Roth, D 
Ammonium per sulphate Sigma Aldrich, D 
Acetylsalicylic acid Sigma Aldrich, D 
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Reagent/Chemical Manufacturer 
Agarose Biozym, D 
Aqua sterile Braun, D 
Bromophenol blue Merck Millipore, D 
Bgl II New England Biolabs GmbH, D 
Bovine serum albumin PAA, A 
Butanol Merck Millipore, D 
Carbenicillin Carl Roth, D 
Celecoxib Cayman Chemicals, D 
cKit magnetic beads Miltenyi Biotec, D 
Collagenase type I Worthington, USA 
Dispase BD Biosciences, D 
DMSO Sigma Aldrich, D 
DAPI Sigma Aldrich, D 
DNAase Macherey-Nagel, D 
ECL reagent westar ηC ultra 2.0 Cyanagen/ 7Bioscience GmbH, D 
EDTA PAA, A 
Ethanol J. T. Baker, D 
Fugene-6 Promega GmbH, D 
FCS Biochrome, D 
G418 Carl Roth, D 
Glycine Merck,D 
Glycerol Merck,D 
Glucose Sigma Aldrich,D 
Heptan Merck,D 
Histamine Sigma Aldrich,D 
Human recombinant IL-3 Peprotech, D 
Human recombinant SCF Peprotech, D 
Ionophore, A23187 Calbiochem, USA 
Isoflurane Abott Laboratories, USA 
KCl Sigma Aldrich, D 
LB Agar Sigma Aldrich, D 
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Reagent/Chemical Manufacturer 
LB Broth Sigma Aldrich, D 
L-glutamine Biochrome, D 
MgCl2 Merck, D 
Methanol Merck, D 
Milk powder Carl Roth, D 
Mouse recombinant IL-3 Immunotools, D 
NaCl Braun 
Na2CO3 Merck, D 
NaOH Carl Roth, D 
Non-essential amino acids Biochrome, D 
ONO-AE1-259-01 EP2 ONO Pharmaceutical Cp.,JP 
ONO-AE-248 EP3 ONO Pharmaceutical Cp.,JP 
ONO-AE1-329 EP4 ONO Pharmaceutical Cp.,JP 
O-Pthalaldehyde Sigma Aldrich, D 
PGE2 Cayman Chemicals, D 
Phosphostop phosphatase inhibitor Roche, D 
PIPES Sigma Aldrich, D 
PMSF Sigma Aldrich, D 
Ponceau S Serva Elektrophoresis, D 
Protease inhibitor Sigma Aldrich, D 
Protein standard Biorad, D 
Penicillin/Streptomycin Biochrome, D 
PVDF membrane GE Healthcare, USA 
SC560 Cayman Chemicals, D 
SDS Sigma Aldrich, D 
TAE-buffer (50X) Genaxxon, D 
TEMED Sigma Aldrich, D 
TNP-BSA Igc, biosearch technologies, D 
Trypan blue Merck, D 
Toluidine blue Merck, D 
Trizma base Sigma Aldrich, D 
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Reagent/Chemical Manufacturer 
Triton-X Merck, D 
Tween-20 Sigma Aldrich, D 
Xba I New England Biolabs, GmbH, D 
 
5.1.4 Antibodies 
Antibody Dilution Factor Manufacturer 
Anti-human IgE 1:500 KPL, USA 
Αnti-mouse IgE 1:500 BD Pharmingen, USA 
Anti-TNP IgE  various BD Pharmingen, USA 
Anti-PTGER2 (H-75) 1:500 Santa Cruz 
Biotechnology, INC., USA 
Anti-PTGER3 (H-200) 1:500 Santa Cruz 
Biotechnology, INC., USA 
Anti-PTGER4 (C-4) 1:500 Santa Cruz 
Biotechnology, INC., USA 
Anti-PTGER2 1:1000 Cayman Chemicals, D 
Anti-PTGER3 1:200 Cayman Chemicals, D 
Anti-PTGER4 1:200 Cayman Chemicals, D 
Anti-PTGER3 1:200/1:500 Atlas Antibodies/Biozol 
GmbH, D 
Anti-PTGER4 1:200/1:500 Atlas Antibodies/Biozol 
GmbH, D 
cKit-APC 1:50 eBioscience,  
Thermo fischer, USA 
Fcγ-Block 1:500 eBioscience,  
Thermo fischer, USA 
FcεRI-PE 1:50 eBioscience,  
Thermo fischer, USA 
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Antibody Dilution Factor Manufacturer 
Goat-anti-rabbit-HRP-
labelled 
1:10000 Chemicon International, 
Thermo fischer, USA 
Human IgE 1:200 Calbiochem, USA 
Rabbit Cyclophilin 1:1000  Cell Signaling 
Technology, D  
Rabbit Phospho-AKT  1:250 Cell Signaling 
Technology, D  
Rabbit Total-AKT  1:250 Cell Signaling 
Technology, D  
Rabbit Phospho-ERK  1:1000 Cell Signaling 
Technology, D 
Rabbit Total-ERK  1:1000  Cell Signaling 
Technology, D  
Rabbit Phospho-P38 1:1000  Cell Signaling 
Technology, D 
Rabbit Total-P38 1:1000  Cell Signaling 
Technology, D 
Rabbit Phospho-PLCγ1 1:1000 Cell Signaling 
Technology, D 
Rabbit Total-PLCγ1 1:1000 Cell Signaling 
Technology, D 
TNP-IgE 1:500  BD Pharmingen, USA 
 
5.1.5 Consumables 
Material Type Manufacturer 
Biosphere filter tips 0.5-20 µl Sarstedt, D 
                2-100 µl  
  100-1000 µl  
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Material Type Manufacturer 
Canula, sterile 21 G, 25G, 26G, 27G, 30G BD, Pharmingen 
Casy tubes  F. Hoffmann – La Roche 
Cell culture flasks 25 cm2, 75 cm2, 175 cm2 Sarstedt, D/ Thermo 
Fisher Scientific, D 
Cell culture pates, sterile 12,48,96 wells Nunc, D 
Combi tips plus 0.5 ml, 5 ml, 10 ml, 12.5 ml Eppendorf, D 
Descosept AF  Dr. Schumacher GmbH, D 
Eppendorf tubes 0.5 ml, 1.5 ml, 2 ml BD Pharmingen, D 
Eppendorf tube stand  TPP 
FACS tubes  Sarstedt, D 
Falcon 15 ml, 50 ml BD, Pharmingen 
Gloves sterile nitrile  Braun 
RT tubes  Qiagen 
Petri dishes  Greiner Bio-one, D 
Pipette tips, sterile  Eppendorf 
Pipetboy  TPP 
Pipettes (0.5-10 μl; 10-100 μl;  
100-1000 μl)  
 Eppendorf 
PVDF membrane 
(Amersham hybond-P) 
 Pharmacia Biotech 
Serological pipettes  5 ml, 10 ml, 25 ml Falcon, Thermo  
fisher Scientific 
Scalpel No.20 Feather, D 
   
Syringes 10 ml, 20 ml, 50 ml BD Pharmingen, D 
Syringe filter  Sarstedt, D 
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Trans blot filter paper  Biorad Laboratories, D 
 
5.1.6 Instruments 
Technical Instrument Model Company 
Agarose gel equipment  Biorad Laboratories, D 
Autoanalyzer II  Borgwald Technik, D 
Autoclave  Melag, D 
Auto-MACS  Miltenyi Bitec, D 
CASY technology cell 
counter 
  TTC Schärfe System 
GmbH 
Chemiluminiscent 
detector 
Fusion FX7 Spectra Vilber Lourmet, D 
Centrifuge Varifuge RF Heraeus,D 
  Megafuge 1.0R  Heraeus D 
Electrophoresis chamber  BioRad Mini Protean 
system 
FACS MACSQuant Analyzer Miltenyi Biotec, D 
Gradient thermocycler Px2 Therma Cycler Thermo Technologies, D 
Incubator HERA cell Heraeus D 
Light microscope Axiovert 10 Carl Zeiss AG, D 
Magnetic stirrer Magnetmix 2070  Hecht-Assistant, D 
Multichannel pipette  Eppendorf 
Nanodrop 
spectrophotometer 
1000 Thermo Fisher Scientific, 
US 
pH-meter pH 1100L VWR International GmbH, 
D 
Pipettes 10 µl, 20µl, 100 µl, 200 µl, 
1000µl 
Eppendorf, D 
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Technical Instrument Model Company 
Power pack HC  Biorad, D 
Rotorgene Q thermocycler R1112155 Qiagen GmbH, D 
Table centrifuge 5417 C Eppendorf, D 
 5417 R  
Thermometer Theralert  TH-5 Physitemp Instruments, 
LLC. USA 
Water bath 3 Julabo, D 
Victor reader multimode 
Plate Reader  
        X3 Perkin Elmer, D 
Vortexer Reax 2000 Heidolph, D 
 
5.1.7 Softwares 
Software Version Company 
CASY-messgerät  1.5 Schärfe System, D 
Image J 1.52 NIH, USA 
FlowJo 7.6.1 Tree Star, USA 
GraphPad Prism 7.00 GraphPad Software, USA 
Microsoft Excel  2016 Microsoft Corporation, USA 
NCBI Databases  National Center for Biotechnology 
Information, USA 
ND-1000 V3.7 Nanodrop, USA 
Primer 3 4.0.0 Source Forge, USA 
UCSC Databases  UCSC Genome Bioinformatics Group 
R statistical platform  The R Foundation 
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5.1.8 Kits 
Kits Manufacturer 
Histamine ELISA Labor Diagnostika Nord, D 
PGE2 EIA Cayman, USA 
Multiscribe Reverse transcription kit Applied Biosystems, Thermo Fischer 
Scientific, D 
Multiplex ELISA Kit Biolegend, Inc., USA 
Nucleospin RNA II kit Macherey-Nagel, D 
Nucleospin plasmid kit Macherey-Nagel, D 
Rotor-gene SYBR green kit Qiagen, GmBH, D 
 
5.1.9 Buffers and Solutions 
Buffer/Solution Composition Manufacturer 
0.5N NaOH 10 g NaOH  
500 ml water 
 
0.5M Tris-buffer 30.285 g tris-HCl  
500 ml water 
 
1X Running buffer 100 ml 10X running buffer 
900 ml water 
 
1X TBS 100 ml 10X TBS  
900 ml water 
 
1X Transfer buffer 100 ml 10x transfer buffer  
200 ml methanol  
700 ml water 
 
1.5 M Tris buffer 90.855 g tris-HCl  
500 ml water 
 
2mM PBS-EDTA 490 ml PBS  
10 ml 100 mM EDTA 
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5X Sample buffer 4% SDS  
100 mM tris-HCL  
20 % glycerol  
200 mM DTT  
0.2 % bromphenol blue 
0.1 % β-mercaptoethanol 
 
1% Perchloric acid 10 ml perchloric acid 
90 ml water 
 
5% Milk in TBST 10 g milk powder  
200 ml 1X TBST 
 
10% APS 10 g APS  
100 ml water 
 
10% SDS 10 g SDS  
100 ml water 
 
10X Running buffer 144 g glycine  
30 g trizma base  
10 g SDS  
1 l water 
 
10X TBS 121.1 g trizma base  
90 g NaCl 
1 l water 
 
10X TBST 1 l- 1x TBS  
5 ml Tween20  
10 l Water 
 
10X Transfer buffer 144 g Glycine  
30 g Trizma Base  
1 l Water 
 
50X PIPES, pH 7.4  1.1M NaCl 
50 mM KCl 
250 mM PIPES 
 
DMEM high glucose  Biochrom, D 
FACS buffer 1% BSA/1X PBS  
IMDM    PAA, A 
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Basal Iscove’s  Biochrom, D 
Lysis buffer   
Medium BMcMCs  IMDM Medium 
10% FCS 
1% P/S 
10 ng/ml IL-3 
0.002% αMTG 
30 ng/ml SCF 
 
Medium HuMCs Basal Iscove’s 
10% FCS 
1% Penicillin/ 
Streptomycin 
2mM l-glutamine 
1% non-essential amino 
acids 
100 ng/ml hrSCF 
 
MACS buffer  0.2% BSA/1X PBS 
20mM EDTA 
 
PBS pH 7.4   PAA, A   
PBS with Ca+2 and Mg+2   PAA, A 
PBST  0.05% Tween/1X PBS   
PAG-CM   1X Pipes 
0.1% Glucose 
0-1% BSA 
 
Ponceau S     0.5 ml Ponceau S  
25 ml Acetic Acid 
500 ml Water 
 
Transport medium IMDM-medium 
10% P/S 
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5.2 Methods 
 
5.2.1 Cell Biology Methods 
 
5.2.1.1 Mast cell isolation and culture 
 
5.2.1.1.1 Human mast cells (HuMCs) 
MCs were isolated from human breast skin or foreskin (cosmetic breast reduction 
surgery or circumcisions). MC isolation and purification was performed using an 
optimized and frequently employed protocol (194-196), giving rise almost to 98-100% pure 
MC preparations. The skin samples were obtained after written consent of patients or 
legal guardians and approved by the University Ethics Committee. Experiments were 
performed according to the Declaration of Helsinki Principles.  
In brief, human skin was cut into strips and treated with dispase (3.5 U/ml) and 4 °C 
overnight. After removal of the epidermis, the dermis was chopped into small pieces 
and digested with collagenase type 1 (10 mg/ml) for 1 h at 37 °C. MC purification was 
achieved by positive selection with mouse anti-human c-Kit-coated microbeads and an 
Auto-MACS separation device. Skin-derived MCs were expanded in basal Iscove’s 
Medium (with 10% FCS, 100 U/mL Penicillin, 100 μg/mL Streptomycin, 2 mM l-
Glutamine, 1% nonessential amino acid solution, stem cell factor (100 ng/ml) and IL-4 
(10 ng/ml) as described previously.(197) The cells were used for the experiments 
described after 3–5 weeks, when proliferation is detectable.(198) The vitality and purity 
of the cells was determined with trypan blue/toluidine blue staining using a light 
microscope and by using a cell counter (CASY). 
 
5.2.1.1.2 Murine bone-marrow derived cultured mast cells 
Murine bone-marrow derived cultured mast cells (BMcMCs) were obtained from female 
C57BL/6J mice using a published protocol. (199) BMcMCs or MC-progenitor-cells are 
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immature and belong to the category of mucosal MCs. (200, 201) They are cultured in 
IMDM medium in the presence of mouse recombinant IL-3 for 4-6 weeks which 
promotes their growth and development (37ºC and 5% CO2 in a humidified 
atmosphere). (17)  
Femur and tibia from a mouse were isolated and cleaned of any tissue remnants. They 
were carried in 50 ml transport medium until further use. All further steps were carried 
out under a sterile airflow bench. The tips of bones were cut and with the help of a 25-
gauge needle and culture medium the bone-marrow was washed out. A 10 ml pipette 
was used to resuspend the bone-marrow in fresh medium followed by centrifugation 
at 1300rpm, 4°C for 10 min in 20 ml medium. The recovered pellet was resuspended 
in 20 ml fresh culture medium and transferred to a 75 cm2 culture flask. To separate 
adherent stromal cells from the suspension MCs, the cell culture medium and the flask 
was changed on Day 5, 8, 10 and 15 and transferred to a new flask. After day 19, the 
medium was changed twice a week, once completely and once 50% alternately. The 
growth factor mrIL3 was added after each medium change at an end concentration of 
10 ng/ml. The vitality of BMcMCs was determined like HuMCs. The purity of BMcMCs 
was determined by the co-expression of c-Kit and FcεRI via FACS (section 3.2.4.3). 
Only cells with a purity >90 % were used for experiments. 
 
5.2.1.2 Histamine release assay 
 
5.2.1.2.1 Pre-treatment of human mast cells with PGE2/EP agonists and 
the analysis of histamine release 
Freshly isolated HuMCs were sensitized with IgE (0.5µg/ml) overnight without 
cytokines. Cells were washed with PAG-CM buffer (pH 7.5), containing 3 mmol/L CaCl2 
and 1.5 mmol/L MgCl2 and treated with various concentrations of PGE2 or EP agonists 
(ONO-AE1–259 (EP-2), ONO-AE-248 (EP-3), ONO-AE1–329 (EP-4), kindly provided 
by Ono Pharmaceutical Company Ltd., Osaka, Japan, for 30 min at 37ºC. Cells were 
stimulated by anti-human IgE antibody (0.5 µg/ml) for 25 min at 37ºC. 
For the assessment of the spontaneous histamine release, cells were kept in buffer 
only. Total histamine content (complete) was determined after cell lysis with 1% 
perchloric acid. The degree of MC stimulability was assessed with calcium ionophore 
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A23187 (2 mmol/L). Cell supernatants were used to determine the histamine release 
using an autoanalyzer. Net histamine release was calculated as follows: Net histamine 
release (%) = [(Stimulated release-Spontaneous release)/Complete] *100. 
 
5.2.1.2.2 Pre-treatment of murine mast cells with PGE2/EP agonists and 
the analysis of histamine and cytokine release 
BMcMCs were sensitized with IgE (1 mg/mL) for 48 h in complete media. Cells were 
washed with PAG-CM buffer (pH 7.5), containing 3 mmol/L CaCl2 and 1.5 mmol/L 
MgCl2 and treated with various concentrations of PGE2 or EP agonists (ONO-AE1–259 
(EP-2), ONO-AE-248 (EP-3), ONO-AE1–329 (EP-4) (alone/in combination) for 30 min 
at 37ºC. BMcMCs were stimulated by anti-IgE (5 µg/mL) for 25 min at 37ºC.  
For the assessment of the spontaneous histamine release, cells were kept in buffer 
only. Total histamine content (complete) was determined after cell lysis with 1% 
perchloric acid. The degree of MC stimulability was assessed with calcium ionophore 
A23187 (2 mmol/L). Cell supernatants were used to determine the histamine release 
using an autoanalyzer. Net histamine release was calculated as follows: Net histamine 
release (%) = [(Stimulated release-Spontaneous release)/Complete] *100. 
For the measurement of cytokines, BMcMCs were treated as above and stimulated 
with anti-IgE for 8 h at 37ºC. 
 
5.2.2 Anaphylaxis in the murine system 
 
5.2.2.1 Mice strains 
Female Balb/c and C57BL/6J mice (10-12 weeks old) were obtained from Charles 
River (Sulzfeld, Germany). Animals were kept under specific pathogen-free conditions 
in a temperature-controlled environment with free access to standard chow and water. 
The local State Office of Health and Social Affairs approved all experiments 
(G0200/11, G0004/16). C57BL/6J mice will be referred to as BL/6 in the following. 
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5.2.2.2 Passive systemic anaphylaxis (PSA) 
 
5.2.2.2.1 Comparison of anaphylactic susceptibility between Balb/c and 
BL/6 mice 
To analyze the anaphylactic susceptibility in the 2 strains of mice, a PSA model (58, 202) 
to induce sub-optimal ANA in these mice was first established. For this purpose, the 
antibody and antigen concentrations were optimized. A consistent amount of anti-
trinitrophosphate (TNP)-IgE (0.8 mg/kg, i.v.) was injected, followed by the injection of 
different doses of TNP-BSA, 24 h later. The systemic ANA reaction was evaluated by 
measuring the core body temperature.(58, 84) Changes in rectal temperature were 
assessed in 10 min intervals for 60 min using a digital thermometer. 
After establishment of the method, mice were passively sensitized with mouse anti-
TNP-IgE (0.8 mg/kg, i.v.) and challenged with an optimized dose of TNP-BSA (0.28 
mg/kg, i.v.), 24 h later. Changes in rectal temperature were assessed. After the 
assessment, mice were euthanized, and serum samples were collected and stored at 
-80°C for further analysis. 
 
5.2.2.2.2 15-PGDH inhibitor and the induction of PSA 
Mice were sensitized with mouse anti-TNP-IgE (0.8 mg/kg, i.v.), on day 1, followed by 
the administration of 15-hydroxyprostaglandin dehydrogenase inhibitor (15-PGDH-I) 
10mg/kg) on day 2. They were challenged by injection of TNP-BSA (0.6 mg/kg, BL/6; 
4 mg/kg, Balb/c, i.v.), 2.5 h later (Fig. 7). Sham groups received DMSO (vehicle) as a 
negative control. Temperature and serum acquisitions were performed as described 
above.  
 
 
 
 
Figure 7:  Experimental model for 15-PGDH-I treatment and the induction of ANA.  
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5.2.2.2.3 Acetylsalicylic acid and the induction of PSA 
BL/6 mice were treated with ASA (50 mg/kg, o.g.) or PBS for different time periods for 
optimization before the induction of systemic ANA (Fig. 8). After the treatment of ASA, 
mice were sensitized with an injection of anti-TNP-IgE (0.8 mg/kg, i.v.) followed by 
TNP-BSA (0.28 mg/kg, i.v.) challenge, 24 h later. Temperature and serum acquisitions 
were performed as described above.  
 
. 
 
 
 
 
 
Figure 8:  Experimental model with ASA treatment and the induction of ANA. 
                                                                                                                       
5.2.2.2.4 PGE2/EP agonists/15-PGDH-I and acetylsalicylic acid-
aggravated PSA 
BL/6 mice were treated with ASA as described above and sensitized with an injection 
anti-TNP-IgE (0.8 mg/kg, i.v.) on day 2 (Fig. 9). Mice were treated with PGE2/EP 
agonists/15-PGDH-I (0.3-7.5 µg/kg, PGE2; 10 µg/kg, EP agonists; 10 mg/kg, 15-
PGDH-I, s.c) or PBS (vehicle) on day 3, followed 45 min or 2.5 h (in case of 15-PGDH-
I) later by TNP-BSA (0.14 mg/kg, i.v.) challenge for the induction of PSA. Temperature 
and serum acquisitions were performed as described above.  
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Figure 9:  Experimental model with PGE2/EP agonists/15-PGDH-I treatment and the induction of 
ANA.  
 
5.2.2.2.5 COX-1/2 inhibitors and acetylsalicylic acid-aggravated PSA 
BL/6 mice were treated with a COX-1 (SC560) or a COX-2 (celecoxib) inhibitor (20 
mg/kg, o.g.) or PBS (vehicle) before the induction of systemic ANA. Animals were 
treated with COX-1/COX-2 inhibitor for 2 days. The last administration was given 24 h 
or 16 h before ANA induction. Mice were sensitized and challenged as described 
above (Fig. 10). 
 
 
 
 
 
 
Figure 10:  Experimental model for COX-1/2 inhibitor treatment and the induction of ANA.  
 
5.2.3 Anaphylaxis patient study 
Sera samples from 27 healthy subjects and 48 patients with a history of hymenoptera 
sting ANA were obtained from the outpatient clinic of the Department of Dermatology, 
Venereology and Allergy. The samples were defined into 4 groups according to their 
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ANA severity grades [Ring and Mesmer (70)]. Severity grading was based on the clinical 
reaction patterns of the most recent ANA episode recorded assessed before first aid 
treatment was given and most patients belonged to severity grades II and III. The 
average age of control subjects and patients was 40 yr. and 48 yr. respectively. All 
patients gave written consent and data/sample acquisition was approved by the Ethics 
Committee at Charité-Universitätsmedizin Berlin. 
 
5.2.4 Analytical methods 
 
5.2.4.1 Histamine measurement using an autoanalyzer 
Histamine can be quantified using an autoanalyzer. (203, 204) This method is based on 
coupling of histamine with o-phthalaldehyde at a highly alkaline pH to form a 
fluorescent product. The fluorescence of histamine-o-phthalaldehyde complex is more 
stable at acidic pH. To remove interfering compounds, histamine is extracted before 
condensation. Protein is removed from the sample using perchloric acid precipitation; 
histamine is extracted into n-butanol and recovered in an aqueous solution of dilute 
HCl by adding heptane. The dilute HCl solution is used for the condensation of 
histamine with o-phthalaldehyde. The extraction procedure removes histidine and 
other interfering compounds before the condensation step. The fluorescence intensity 
of the histamine-o-phthalaldehyde complex is directly proportional to the histamine 
level in samples and is detected by a computer. By using histamine standards, the 
histamine concentration in samples can be determined. 
 
5.2.4.2 Quantification of prostaglandins, mast cell mediators and 
cytokines by ‘Enzyme-linked immunosorbent assay’ (ELISA) 
For the measurement of histamine and PGE2 in serum, competitive ELISAs were used. 
These assays are based on the competition between the antigen in the samples and 
standards which are bound to the solid carrier or added, for a fixed number of antibody 
binding sites. After the system is in equilibrium, free antigen and free antibody-antigen 
complexes are removed by washing. The antibody bound to the solid carrier can be 
detected by an enzyme-conjugated secondary antibody using a substrate. The 
substrate is converted into a colored product and its absorbance is measured. The 
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intensity of the color developed is positively correlated to the amount of enzyme and 
inversely proportional to the concentration of the target molecule in the test sample. 
The quantification of samples is achieved by comparing their absorbance with values 
from the standard curve prepared with known concentrations. 
For the detection of cytokines, BMcMCs were pre-treated as mentioned in section 
6.2.1.2.2, but stimulated with anti-IgE for 8 h. The amounts of TNF-α, IL-6, IL-13, CCL-
2 and CCL-3 were determined in supernatants following manufacturer’s instruction 
using a multiplex ELISA. 
 
5.2.4.3 Flow cytometry analysis of mast cells 
Flow cytometry is an optical technique used for the analysis of single cells in a cell 
suspension. Cells are labelled with antibodies conjugated to fluorescent molecules 
called fluorochromes, which absorb light of a particular wavelength to emit light of 
another wavelength known as excitation and emission. Flow cytometry allows the 
detection and separation of a cell labelled with fluorochromes. This technique uses 
lasers to excite fluorochromes tagged to the cells, which emit light, recorded by a 
detection system. Since the cells pass one by one through the laser, the machine 
keeps count of cells and the level of fluorescence produced. For the detection of 
specific extracellular or intracellular proteins, cells can be marked and identified with 
different fluorochrome-conjugated antibodies. (205)  
To determine the purity of BMcMCs, 500,000 cells were used per sample. They were 
washed with 1X PBS and centrifuged at 2400 rpm, 4°C for 10 min. Cells were 
incubated with FcR block for 15 min at 4ºC and subsequently stained with 
fluorochrome-labelled FcεRI-PE and cKIT-APC Cy7 antibodies against MC specific 
markers FcεRI (IgE receptor) and cKIT (KIT receptor) for 30 min at 4ºC.  Antibody with 
the same isotype was used to stain control samples. Simultaneously cells were stained 
with DAPI to determine living cells. After the staining, cells were washed and measured 
with the MACSQuant Analyzer. The data was analyzed using FlowJo software. Cells 
double positive for both FcεRI and cKIT were considered MCs. 
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5.2.5 Molecular Biology Methods 
To determine EP receptors’ expression, a quantitative real time polymerase chain 
reaction (qRT-PCR) was performed. Ribonucleic acid (RNA) was isolated from 
human/murine MCs and transcribed into complementary DNA (cDNA) as a template 
for the qPCR reaction. 
 
5.2.5.1 Isolation of ribonucleic acid 
1*106 cells (BMcMCs or HuMCs) were washed with 1X PBS and centrifuged at 1300 
rpm, 4°C for 10 min. The pellet was resuspended in 350 µl lysis buffer (RA1, 
NucleospinRNA II) with 3.5 µl β-mercaptoethanol (β-ME). The RNA isolation was 
performed according to protocol of the Nucleospin RNA II kit. RNA was eluted with 30 
µl RNAse-free water passed through the column two times. 
 
5.2.5.2 Synthesis of complementary cDNA 
Synthesis of cDNA was performed using Taqman reverse transcription reagents, with 
a multiscribe reverse transcriptase enzyme. Maximum 1µg RNA was taken in a volume 
of 7.7 µl with 12.3 µl reaction mix (Table 2) and incubated in a thermocycler according 
to the protocol of cDNA synthesis. cDNA was stored at -20°C until further usage. 
 
Reagent Volume (µl) Endconcentration 
10x Taqman RT buffer  2.0 1x 
25 mM MgCl2 4.4 3-6 mM 
10 µM deoxyNTPs 4 2 µM 
50 µM RandomHexamer primer 0.5 1.25 µM 
50 µM Oligo d(T)16 Primer 0.5 1.25 µM 
20 U/µl RNAse Inhibitor 0.4 0.4 U/µl 
50 U/µl MultiScribe reverse 
transcriptase 
0.5 1.25 U/µl 
Table 2: Reaction mix for Reverse Transcription 
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5.2.5.3 Quantitative polymerase chain reaction (qPCR) 
qPCR is performed to analyze the expression of genes using cDNA as a template. This 
technique uses sybr green, a fluorescent double-stranded DNA intercalating dye, that 
fluoresces once bound to the DNA. A pair of gene-specific primers are used to amplify 
the template DNA. The amount of dye incorporated is directly proportional to the 
amount of product formed. The dye emits at 520 nm and fluorescence emitted can be 
measured and related to the amount of product formed. The DNA template was diluted 
1:3 and mixed with specific primers and sybr green mix from Quantitech SYBR green 
PCR kit. The reaction mix (Table 3) was then incubated in the Rotor gene Q (QIAGEN 
GmbH, Hilden, Germany).  
 
Reagent Volume (µl) End Concentration 
2x Rotor-Gene SYBR Green 
PCR Master Mix 
5 1x 
10 µM Primer, forward 1 1 µM 
10 µm Primer, reverse 1 1 µM 
H2O 1  
Table 3: Reaction mix for a qPCR reaction 
 
All primers used (Table 4) were oligonucleotide primers designed with the help of the 
Primer3 software and purchased from TIB Molbiol, Berlin, Germany. Specific 
conditions for each primer are mentioned in the table below: 
 
Gene Sequence (5’-3’) Size 
(bp) 
Conditions 
TDen/TAn/TEx 
  tDen/tAn/tEx 
TBP    for: TTTGTGCCAGATACATTCCG 
rev: AACAATTTACAAGCTGCGTTT 
127 95/60/72 
10/10/10 
mEP2 for: GACGGACCACCTCATTCTC  
rev: CTAAGTATGGCAAAGACCCAAG 
180 95/65/72 
10/10/10 
mEP3   for: ATGATGGTCACTGGCTTCGT 
rev: ATGGTTAGCCCGAAGAAGGT 
239 95/60/72 
10/10/10 
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mEP4 for: ATCTTACTCATCGCCACCTCTC 
rev: ATCTGGGTTTCTGCTGATGTCT 
 95/65/72 
10/10/10 
hHPRT    for: CCTGGCGTCGTCATTAGTGA 
rev: GCCTCCCATCTCCTTCATCA 
162 95/65/72 
10/10/7 
hEP2   for:  CCACCTCATTCTCCTGGCTA 
rev:  CGACAACAGAGGACTGAACG 
216 95/63/72 
10 /10/5 
hEP3   for:  GGATCATGTGCGTGCTGTC 
rev:  TGCTTCTCCGTGTGTGTCTT 
109 95/63/72 
10/10/5 
hEP4 for: TCATCTTACTCATTGCCACCTC 
rev: ACTGACTTCTCGCTCCAAACT 
110 95/63/72 
10/10/5 
mCCL-2 for: AGCACCAGCCAACTCTCACT 
rev: TCATTGGGATCATCTTGCTG 
184 95/58/72 
10/10/5 
mCCL-3 for: CAGCCAGGTGTCATTTTCCT 
rev: CTCAAGCCCCTGCTCTACAC 
170 95/62/72 
10/10/5 
mIL-13 for: CAGCTCCCTGGTTCTCTCAC 
rev: CCACACTCCATACCATGCTG 
212 95/58/72 
10/10/5 
mIL-8 for: ATGCCTCTCCATTTCCTGCT   
rev: CATGGGGAAAGAGGCTCTGA   
155 95/60/72 
10/10/5 
TNF-α for: CCACCACGCTCTTCTGTCTA 
rev: GGTTGTCTTTGAGATCCATGC   
198 95/60/72 
10/10/5 
Table 4: Primer sequences for qPCR 
 
The expression levels of the target genes were quantified relative to the expression of 
a reference gene using the 2-ΔΔCT method. 
 
5.2.5.4 Transfection 
HEK 293S cells were stably transfected with EP2-4 cDNA clones to generate positive 
controls for studying EP receptor expression in MCs. 
 
5.2.5.4.1 Clone preparation 
Empty pTCN vector and pTCN-EP receptor 2-4 cDNA clones were purchased as 
glycerol stocks from transOMIC Technologies. The pTCN vector has a CMV promoter 
and resistance for prokaryotic and eukaryotic systems (carbenicillin/neomycin). The 
details of this vector can be seen in Fig. 11.   
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Figure 11: Detailed map of pTCN vector (transOMIC technologies). pTCN is a 5193 bp long high 
copy plasmid with a CMV promoter for cDNA expression. It has a poly A element to provide 
polyadenylation signal for mRNA stabilization and SV40 promoter to drive selective marker expression. 
The selection marker provided in this vector is neomycin and has pUC ori for propagation in E. coli. 
Ampicillin is the bacterial selection marker to be used. 
For the amplification of cDNA clones (Fig. 12), 200 µl pre-warmed LB medium was 
inoculated with the glycerol stocks and spread on LB agar plates containing 
carbenicillin (100 µg/ml). After overnight incubation at 37°C, single colonies appeared 
on the plate. Three single colonies were used to inoculate three, 5 ml LB broth starter 
cultures containing 5 µl carbenicillin. After overnight incubation at 37°C with shaking, 
these cultures were used for plasmid purification according to the instructions using 
NucleoSpin Plasmid kit. The potential clones were confirmed using double restriction 
digestion and sequencing. Restriction digestion was performed using enzymes Xba I 
and Bgl II. 1 µg DNA was incubated with 4 µl master mix according to instructions for 
the enzymes and products were visualized using a 1% agarose gel. Clones were 
confirmed by sequencing with the help of Eurofins Genomics. 
 
 
 
 
 
Figure 12: Preparation of cDNA clones 
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5.2.5.4.2 Stable transfection 
2.5*104 HEK 293S cells/well were plated in 1 ml DMEM high glucose complete medium 
in a 12-well cell culture plate and incubated for 24 h at 37°C in a CO2 incubator such 
that they are 50% confluent after 24 h.  Cells were washed with 1x PBS and the media 
was replaced with 950 µl antibiotic-free DMEM high glucose media. Cells were 
transfected using Fugene-6 transfection reagent. To prepare the transfection complex 
two complexes were prepared. Complex 1 included 1µg DNA in 25 µl antibiotic-free 
DMEM medium. Complex 2 contained 3 µl Fugene-6 transfection reagent in 22 µl 
medium. The two complexes were incubated together for 15-20 min after which the 
mix was added to the cells drop-wise with shaking. The cells were incubated for 48 h 
at 37°C in a CO2 incubator. After 48 h, cells were washed with 1x PBS and 1 ml 
complete DMEM medium was added together with 1 mg/ml G418. Cells were fed every 
3 days for 2.5 weeks. Cells were serially diluted in 100 µl complete medium in a 96-
well plate to attain limiting dilution. Single cell clones were expanded. 
Stably transfected HEK 293S-EP2, HEK293S-EP3, HEK293S-EP4 cells were checked 
for the enhanced expression of EP receptors by using qPCR (section 6.2.5.3) and 
immunoblotting (section 6.2.5.5). 
 
5.2.5.5 Immunoblotting (IB) and Immunoprecipitation (IP) 
IB was used to analyze the expression of EP receptors and the phosphorylation of 
proteins in MCs. 
EP receptor expression 
To establish the protocol and test the antibodies for EP receptor expression, HEK293 
cells stably transfected with EP receptors were used as positive controls. In order to 
isolate EP 2-4 receptor proteins from cell lysate, IP was used prior to detection by IB.  
IP 
IP is a technique used to isolate a specific antigen from a mixture, using antigen-
antibody interaction. Antigens isolated are then analyzed by IB. Around 30-35*10^6 
HEK-EP (2-4) overexpressed cells (~900µg-1mg protein) were lysed in 1 ml of lysis 
buffer. Protein G magnetic beads (0.25 mg) were washed and separated using a 
magnetic stand. Beads were then incubated with specific antibody (anti-EP 2-4, 5 µg) 
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together with wash buffer (1 ml) and incubated for 2-4 h, at 4°C with mixing. The 
magnetic beads were then separated using a magnetic stand and combined with the 
cell lysate together with the wash buffer (1 ml). The lysate was incubated with an 
irrelevant antibody as a negative control. The mixture was incubated overnight at 4°C 
with mixing. The beads were collected again using a magnetic stand and the flow-
through was removed (collect for analysis). The magnetic beads were washed 3x with 
500 µl of wash buffer and separated using a magnetic stand. The supernatant was 
removed carefully. 500μL of ultrapure water was added to the tube and gently mixed. 
The beads were collected discarding the supernatant. The wash was repeated twice. 
EP proteins were eluted by adding 50 ul SDS sample buffer (1X) and heating for 10 
min to 95°C. The beads were magnetically separated and the supernatant for further 
used for Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
IB 
To detect EP receptors, eluted proteins were separated through a 10% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the 
proteins were transferred to PVDF membranes. The membranes were blocked with 
5% milk and incubated with corresponding primary antibodies (Cayman/Santa 
Cruz/Atlas) overnight and subsequently with (1: 7500 diluted) HRP (horseradish 
peroxidase)-conjugated secondary antibody for 1h. Finally, blots were visualized by a 
chemiluminescence assay (ECL) according to the manufacturer’s instructions, and the 
bands were recorded using a detector for chemiluminescence. To quantitate changes 
in expression blots images were quantified using ImageJ (1.48v). Arbitrary values were 
determined using the following equation:  
                            Relative target expression =          density target           
                                                                      density housekeeping gene                               
 
Protein levels were normalized to β-actin by using densitometry. Images were cropped. 
The conditions shown in Table 5 were used to optimize the detection of EP receptors 
2-4 using IP+/- IB. 
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Technique Reagents  Condition/s 
IB Antibodies from 
Cayman Chemicals 
Titration (EP2-1:200-1:20000, EP3- 
1:200-1:2000, EP4- 1:200-1:2000) with 
different concentrations of protein.  
(10, 60µg, 100µg, 150µg)  
IB Antibodies from Santa 
Cruz (S/C) 
Titration (EP2-1:100-1:2000, EP3- 1:200-
1:1000, EP4- 1:200-1:1000). 
IP+IB Combinations of 
Cayman and S/C 
antibodies, Protein G 
beads  
Cayman Ab+ S/C Ab, Cayman Ab 
+Cayman Ab, S/C Ab+ Cayman Ab, S/C 
Ab+ S/C Ab, Cayman + only secondary 
Ab, S/C Ab+ only secondary Ab 
IB Antibodies from Atlas 
Antibodies 
Titration for EP3/4 with Atlas antibodies. 
Table 5: Summary of conditions used to optimize the detection of EP receptor 2-4 expression in 
HEK293-EP 2-4 overexpressed cells. IP, immunoprecipitation; IB, immunoblotting. 
 
Protein phosphorylation 
To check the expression of phosphoproteins in BMcMCs, cells were sensitized with 
mIgE (1mg/mL) for 48 h, washed and resuspended in PAG-CM buffer.  They were pre-
incubated with 0.5/1/10 ng/ml of PGE2 for 2 min and stimulated with anti-IgE (0.5 
µg/mL) for an additional 15 min at 37ºC. The reaction was stopped with ice-cold 1X 
PIPES buffer and the cell pellet was processed for lysis. MCs were lysed and 
separated through 10% SDS-PAGE. The transfer, blotting and development 
procedures were same as mentioned above. 
 
5.2.5.6 Statistical analysis 
Paired samples in two groups were analyzed using a paired t-test (normal distribution) 
or the Wilcoxon matched-pairs signed rank test (non-parametric). Unpaired samples 
were analyzed using an unpaired t-test or Mann-Whitney rank test (non-parametric). 
Multiple experimental groups were analyzed by ANOVA/Kruskall Wallis test followed 
by Dunn-Sidak post-test. The core body temperature measurements in the PSA model 
were analyzed by 2-way ANOVA followed by a Sidak’s test. Figures 15A and 17A were 
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analyzed by comparing the delta of area under the curve using Wilcoxon rank sum test 
with continuity correction. A p-value of 0.05 was considered statistically significant. 
Statistical analyses were performed using GraphPad software (version 7.0; GraphPad 
Software, La Jolla, Calif) and R Statistical Platform (206). 
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6. RESULTS 
 
6.1 Relative lack of PGE2 pre-disposes to 
anaphylaxis 
 
6.1.1 Anaphylaxis patients display low levels of serum 
PGE2 
Compromised production of PGE2 has been linked to the aggravation of rhinitis and 
asthma in patients of ASA-induced hypersensitivity. (170, 171) Other evidence regarding 
the role of COX inhibition in allergy and asthma also highlights PGE2 as a possible 
cofactor. (135, 165)  In order to study any alterations in PGE2 levels associated with ANA, 
we analyzed sera samples from 27 healthy donors and 48 patients with a history of 
hymenoptera sting ANA (ANA-prone) for their levels of PGE2 (section 5.2.3). ANA 
patients exhibited substantially lower levels of the lipid mediator in comparison with 
healthy controls (324.7 ± 33.73 pg/ml vs 142.3 ± 14.11 pg/ml) (Fig. 13A). The 
correlation of PGE2 serum levels with the severity of the anaphylactic reaction in these 
patients revealed a tendency of an inverse correlation (r= -0.33) between PGE2 values 
and the severity of the reaction (Fig. 13B). 
 
 
 
 
 
 
 
 
Figure 13: Anaphylaxis is characterized by PGE2 deficiency. A) Serum levels of PGE2 in sera of 
healthy control subjects (27) compared to ANA patients (48; outside of acute reaction), measured by 
ELISA. The data are shown as dot plots where each dot corresponds to one individual and median 
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depicted by column. B) Serum levels of PGE2 as a function of severity of the most recent anaphylaxis 
episode recorded. ****P<0.0001. 
6.1.2 Comparative analysis of anaphylaxis using 
BL/6/Balb/c mice 
To study the role of a given genetic background in ANA, we compared two strains of 
mice frequently used as models of allergic disease, BL/6 and Balb/c. Animal studies 
investigating allergic diseases have shown these strains to differ in their immune 
responses. (207-211) A PSA model was used to compare the severity sub-optimal ANA 
in these mice. For this purpose, the dose of antigen was optimized. Mice were injected 
intravenously with a consistent amount of anti-TNP-IgE (0.8mg/kg), 24 h after which, 
both strains of mice were challenged with different doses of TNP-BSA. As a measure 
of systemic ANA, the core body temperature was measured every 10 min for a period 
of 60 min and plotted against the dose of antigen. As shown in figs. 14A and 14B for 
Balb/c and BL/6 mice respectively, the anaphylactic reaction (core body temperature 
versus time) follows a Gaussian distribution curve.  
Figure 14: Dose response curves for TNP-BSA. Female A) Balb/c mice B) C57BL/6J mice were used 
to induce ANA with different doses of TNP-BSA. Rectal temperature assessment is shown as a function 
of time. (A, n=1/group; B, n=1/group [n=3 {6 g, 7g}]) 
The intensity of the anaphylactic reaction (reflected by the drop in core temperature), 
increased with increasing doses of the allergen reaching a maximum of 5.8°C at 50µg 
in Balb/c mice and 4.6°C at 10µg in BL/6 mice and decreasing thereafter. In Balb/c 
mice, 4µg of allergen elicited a temperature drop of 2.4°C; 7µg TNP-BSA caused a 
drop of 3°C. The maximal temperature drop was observed using 50µg TNP-BSA. On 
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the contrary, in BL/6 mice, 5 µg allergen resulted in a drop of 0.2°C and increased to 
3.6°C with 7µg of allergen, reaching a maximum of 4.7°C with 20µg allergen. A 
temperature drop of 3-4°C is sufficient, to observe the effect of cofactors of ANA, 
therefore, a dose of 7µg TNP-BSA was used in all further PSA experiments. 
 
6.1.3 BL/6 display a higher susceptibility towards 
anaphylaxis than Balb/c mice 
Balb/c and BL/6 mice are two commonly used mouse strains to study hypersensitivity 
reactions like asthma or ANA. They are known to vary in the intensity of allergic 
responses. (207-213) A comparison of the severity of ANA between the two mouse strains, 
show a clear difference when using PSA. BL/6 mice exhibited a higher drop in core 
body temperature (Fig. 15A) when treated with similar dose of allergen (7µg) than 
Balb/c mice. This higher drop of temperature was accompanied by higher levels of 
serum histamine (Fig. 15B) indicating an increased response of the effector cells in 
BL/6 compared to Balb/c mice. The drop in core body temperature is used as a readout 
for anaphylactic reaction in the PSA model and was confirmed by the increased 
histamine levels. 
Figure 15: C57BL/6J mice develop more severe anaphylaxis than Balb/c. A) Core body temperature 
assessment shown as a function of time. The data are given as mean ± SEM, n=10-12. B) Serum levels 
of histamine upon elicitation of anaphylaxis, as determined by ELISA. The data are shown as dot plots 
with the median depicted as column. *P< 0.05, **P<0.01. 
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6.1.4 BL/6 mice display lower levels of serum PGE2 
An impaired production of PGE2 has been reported to play a role in ASA-induced 
hypersensitivity reactions.(159, 170, 172) To investigate whether differences in PGE2 levels 
are responsible for the variation in ANA intensity, two mouse strains were compared 
regarding their basal PGE2 serum concentrations. We found significantly lower levels 
of PGE2 in BL/6 mice (154.9 ± 21.46 pg/ml) as compared to Balb/c (494.4 ± 63.67 
pg/ml) (Fig. 16). The data suggests that variation in PGE2 levels among genotypes 
may contribute to the differential susceptibility of the strains towards anaphylactic 
reactions. 
 
 
 
 
 
 
 
 
Figure 16: C57BL/6J display lower levels of PGE2 in comparison to Balb/c mice. Serum levels of 
PGE2 at baseline were determined by ELISA and compared between Balb/c and C57BL/6J mice. The 
data are shown as dot plots with the median depicted as column. n= 16-17. ****P<0.0001. 
 
6.1.5 Elevation of PGE2 inhibits PSA in BL/6 mice 
The above data suggest that the reduced PGE2 may be relevant for the outcome of the 
ANA severity. To confirm this hypothesis, ANA-prone BL/6 mice were treated with an 
inhibitor of the 15-PGDH enzyme, responsible for PGE2 degradation, which leads to a 
stabilization of PGE2. By using this approach, we were indeed able to raise PGE2 
serum levels in BL/6 mice (data not shown). The inhibitor reverted the drop in core 
body temperature and resulted in faster recovery from ANA in BL/6 mice (Fig. 17A). 
This observation was accompanied by attenuated histamine release (Fig. 17B), 
matching the outcome of core body temperature. The inhibitor did not increase PGE2 
levels in Balb/c mice suggesting a low 15-PGDH activity. We were not able to 
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determine any effect on the development of ANA. However, more animals are needed 
to confirm these results (Figs. 17C/D). Taken together, these findings suggest that 
ANA susceptibility in BL/6 mice is at least partially influenced by PGE2, whose 
augmentation can protect against ANA.  
 
 
 
 
 
 
 
 
 
 
Figure 17: Stabilization of PGE2 inhibits anaphylaxis in C57BL/6J mice. A-B) C57BL/6J and C-D) 
Balb/c mice were treated with 15-PGDH-inhibitor or vehicle, prior to PSA induction. Core body 
temperature measurement is shown as a function of time. The data are shown as mean ± SEM, A, n=6-
8; C, n=4-7 B/D) Serum histamine levels upon elicitation of anaphylaxis were determined by means of 
ELISA. The data are shown as dot plots with the median depicted as column. **P<0.01. 
 
6.2 PGE2 decreases ASA-mediated aggravation of 
anaphylaxis 
 
6.2.1 Acetylsalicylic acid aggravates PSA in BL/6 mice 
As shown in our in vivo murine experiments in section 7.1.3, BL/6 mice are more 
sensitive towards developing anaphylactic reactions and are therefore most likely a 
better choice to study ANA in comparison to Balb/c. Our results suggest that low basal 
levels of PGE2 in BL/6 mice pre-dispose to ANA, and an increase of endogenous PGE2 
alters the outcome of the reaction. Therefore, to further validate the protective role of 
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PGE2 in ANA, BL/6 mice were treated with ASA, a well-known inhibitor of 
cyclooxygenases, and thereby the production of PGE2. 
To study the impact of ASA in the PSA model, BL/6 mice were treated with ASA or 
PBS (vehicle) as a negative control for different time durations (3 days until 24 h, 16 h 
or 90 min before the induction of systemic ANA) for optimization. Mice were treated 
with ASA before the induction of systemic ANA and the core body temperature was 
measured. Treatment with ASA aggravated the drop in core body temperature (5.9°C) 
in comparison to the vehicle-treated mice (4.3°C) (Fig. 18). The maximal aggravation 
in temperature drop (2.1°C) was detected in mice treated with ASA for 3 days with the 
last administration 90 min prior to the induction of ANA. Altogether, the data indicates 
that ASA aggravates hypothermia and hence ANA in BL/6 mice. 
 
 
 
 
 
 
 
 
Figure 18: ASA aggravates anaphylaxis in C57Bl/6J mice. Female C57BL/6J mice were treated with 
ASA, (or PBS as a negative control) and PSA was induced. Core body temperature measurements are 
shown as a function of time. The data are shown as mean ± SEM. n=16-17. *P< 0.05, ****P<0.0001 
(ANA; PBS-treated versus ANA/ASA; ASA-treated). 
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6.2.2 PGE2/EP agonists 2/3 ameliorate ASA-mediated 
aggravation of anaphylaxis 
To validate the protective impact of PGE2 on ASA-aggravated ANA, mice were treated 
with ASA followed by the administration of various doses of PGE2 before the induction 
of systemic ANA. PGE2 was administered 90 min before the induction of ANA and the 
core body temperature was measured. PGE2 treatment reduced the drop of the core 
body temperature caused by ASA from 5.5°C to 2.4°C, hence protecting against the 
exacerbation of ANA by ASA (Fig. 19A). Importantly, not only the administration of 
exogenous PGE2 protected against the severity of ANA, the stabilization of 
endogenous PGE2 by means of 15-PGDH-I similarly reduced ANA severity (5.95°C to 
4.85°C) (Fig. 19B). These observations confirm our hypothesis that an increase of 
PGE2 can protect mice against the severity of ANA. 
Figure 19: PGE2 suppresses the potentiation of anaphylaxis by ASA. Female C57BL/6J mice were 
treated with ASA and A) PGE2 B) 15-PGDH-I, (or PBS as a negative control) and PSA was induced. 
Core body temperature measurements are shown as a function of time. Data are shown as mean ± 
SEM. n=6-16 per group. *P< 0.05, ****P<0.0001 (ANA; PBS-treated versus ANA/ASA; ASA-treated); 
###P<0.001, ####P<0.0001 (ASA/PGE2/ANA; ASA+PGE2-treated versus ANA/ASA); §P<0.05 
(ASA/PGE2/ANA versus ANA). 
 
PGE2 exerts its effects via different EP receptors. EP2, EP3 and EP4 have been 
described previously to be broadly expressed throughout the body (214, 215) and to 
exhibit distinct actions in the context of allergy and asthma. (156, 216) To pinpoint the EP 
receptor responsible for the protective effect of PGE2, mice were treated with ASA, 
followed by the administration of specific EP 2-4 receptor agonists (166, 217-220), 45 min 
before the induction of ANA. Treatment with EP2 agonist as expected reduced 
hypothermia (6.48°C to 4.37°C) preventing the aggravation of ANA by ASA (Fig. 20A). 
However, the effect of EP4 agonist was not significant (6.48°C to 5.66°C) despite a 
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slight tendency for protection (Fig. 20C). In contrast, the EP3 agonist was most potent 
(6.48°C to 4.19°C), reducing the aggravation of ANA by ASA (Fig. 20B). Overall, the 
data indicates that PGE2 mediates its protective effect through EP receptors 2-4.  
Figure 20: EP-Agonists moderate aggravation of anaphylaxis by ASA. Female C57BL/6J mice 
were treated with ASA and A) EP2 agonist B) EP3 agonist C) EP4 agonist (or PBS as a negative control), 
and PSA was induced. Core body temperature measurements are shown as a function of time. The 
data are shown as mean ± SEM. n=5-8 per group. ***P< 0.001, ****P<0.0001 (ANA; PBS-treated versus 
ANA/ASA; ASA-treated); ##P<0.01, ###P<0.001, ####P<0.0001 (EPX/ASA/ANA; EPX agonist-treated 
versus ASA/ANA). 
 
6.2.3 COX-1/2 inhibitors aggravate PSA in BL/6 mice 
ASA/NSAIDs act by inhibiting enzymes known as cyclooxygenases which exist in two 
isoforms namely COX-1 and COX-2. (133) To determine which COX (COX-1/2) subset 
is responsible for the impact of ASA on ANA in BL/6 mice, mice were treated with 
specific COX-inhibitors. SC-560 was used for COX-1 and celecoxib for COX-2 for 2 
days. The last administration was given 24h before the induction of ANA and the core 
body temperature was measured. Both COX-1/2 inhibitors increased hypothermia in 
mice (COX-1: 5.9°C; COX-2: 6.2°C), almost to a similar degree as caused by ASA 
(6.5°C). The effect of COX-1 inhibitor was rapid reaching significance with 5.4 °C after 
20 min and disappeared earlier (Fig. 21A), whereas the COX-2 inhibitor virtually 
mimicked ASA, reaching significance after 30 min (Fig. 21B). These results suggest 
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that the impact of ASA on systemic ANA is related to the inhibition of both COX-1 and 
COX-2 enzymes. 
Figure 21: COX-1/2 inhibitors aggravate anaphylaxis. Female C57BL/6J mice were treated with A) 
COX-1 inhibitor B) COX-2 inhibitor, (or PBS as a negative control) and PSA was induced. Core body 
temperature measurements shown as a function of time. The data are shown as mean ± SEM. n=8-11, 
****P<0.0001 (ANA; PBS-treated versus ANA/ASA; ASA-treated); #P<0.05, ##P<0.01, ###P<0.001, 
####P<0.0001 (ANA versus ANA/COX-1/2; COX-1/2-treated). 
 
6.3 PGE2 partially reduces anaphylaxis via its effect 
on mast cells 
  
6.3.1 PGE2 reduces mast cell activation in BL/6 mice 
unlike Balb/c-derived cells 
MCs release preformed as well as de novo synthesized mediators and cytokines, upon 
activation. To pinpoint the mechanism of PGE2-mediated amelioration of ANA and find 
out if MC responses are differently regulated in these strains, BMcMCs from BL/6 and 
Balb/c mice were used to study MC responses towards PGE2. Cells were treated with 
various concentrations (0.05-10 ng/ml) of PGE2 prior to MC activation. Histamine and 
cytokine release were analyzed in cell supernatants to measure cell activation. As 
expected, upon MC activation with anti-IgE, all assessed mediators (histamine, TNF-
, IL-13, CCL-2, CCL-3 and IL-6) were increased in cells from both strains (data not 
shown). However, treatment with PGE2 prior to MC activation by anti-IgE led to 
opposing effects, showing a decrease in histamine as well as TNF-α release in BL/6 
mice but an increase in Balb/c mice (Fig. 22). There were no differences in the release 
of other cytokines- IL-6, IL-13, CCL-2 and CCL-3 (data not shown). Similarly, the pre-
treatment of BMcMCs with PGE2 alone did not significantly change the spontaneous 
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release of histamine or cytokines in either strain (data not shown). This suggests that 
the suppressive effect of PGE2 in mice is most likely a result of its impact on MCs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22: PGE2 exhibits opposing effects in different strains of mice. BMcMCs from C57BL/6J 
and Balb/c mice were sensitized and pre-incubated with A) different concentrations of PGE2 followed by 
anti-IgE stimulation for 30 min. Histamine release was quantified by an autoanalyzer-based method. 
The net release was determined in the following way ‘Net release= [stimulated release- spontaneous 
release] in %total’. B) PGE2 for followed by anti-IgE stimulation for 8h and TNF-α production was 
measured using ELISA. The data are shown as mean ± SEM, n=5-7 per group. *P< 0.05 and **P<0.01. 
 
6.3.2 EP receptor expression profile is comparable in 
BL/6- and Balb/c-MCs 
The characteristic pattern of expression of PGE2 receptors, EP 1-4 and their relative 
ratios in different cells and tissues are known to govern the diverse cellular functions 
of PGE2 (151-154). To assess whether a different EP receptor expression is responsible 
for the opposing effect of PGE2 in MCs, we analyzed the relative expression of EP1-4 
in BMcMCs from BL/6 and Balb/c mice. Both strains exhibited a comparable 
expression pattern for EP receptors (Fig.23), with a low expression of EP2 receptor 
but a strong and comparable expression of EP receptor 3 and 4. Almost no expression 
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of EP1 receptor was found (data not shown). The expression of EP3 receptor was 
higher in Balb/c mice compared to BL/6 mice (~1.75 fold). 
 
 
 
 
 
 
 
 
Figure 23: EP receptor expression profile is comparable in BL/6- and Balb/c- MCs. EP receptor 
expression in BMcMCs was assessed via real time PCR and normalized to the expression of TBP. The 
data are shown as means ± SEM, n=9. 
 
6.3.3 Impact of PGE2 in BL/6 mice is mediated by 
EP2/EP4 receptors 
PGE2 receptors have distinct and partially opposite downstream signaling pathways. 
Their functional differences are known to impact the effects of PGE2 (130). To pinpoint 
the specific receptor/s responsible for the impact of PGE2, BMcMCs were treated with 
specific EP 2-4 agonists, alone or in combination and MCs were stimulated. EP3 
agonist stimulated histamine release in MCs from both strains. EP2 and EP4 agonists, 
however, significantly inhibited histamine release in BMcMCs from BL/6 mice 
(Fig.24A), but not from Balb/c mice. This effect was even more pronounced upon 
combination of both agonists (Fig. 24B). In contrast, the combination did not 
significantly reduce the release of histamine in BMcMCs from Balb/c mice. 
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Figure 24: Impact of PGE2 In C57BL/6J mice is mediated by EP2/EP4 receptors. BMcMCs from 
C57BL/6 and Balb/c mice were sensitized and pre-incubated with A) different EP agonists. B) EP2 and 
EP4 agonists combined. MCs were stimulated with anti-IgE and histamine release was quantified by an 
autoanalyzer-based method. The net release was determined in the following way ‘Net release = 
[stimulated release – spontaneous release] in % of total’. The data are shown as mean ± SEM, n=5-7 
per group. *P< 0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
 
6.3.4 Anti-IgE mediated phosphorylation of PLCγ1 and 
ERK 1/2 is reduced by PGE2 
 As PGE2 impacts IgER-mediated MC activation, we examined the downstream 
signaling events in MCs to elucidate the mechanism of action of PGE2. FcεRI mediates 
signaling by the initial activation of tyrosine kinases like Syk, Lyn and Fyn (Fig. 2) 
leading to the phosphorylation and activation of downstream enzymes. Degranulation 
is tightly regulated by two enzymes, PLCγ and PI3K, whereas the MAP kinases 
ERK1/2, JNK and p38 are involved in cytokine gene transcription (Fig. 2).(16) We 
verified that FcεRI-aggregation induced phosphorylation of PLCγ1, PI3K, MAP kinase 
ERK1/2 and p38 in cells from both the strains (Figs. 25/26). To study the impact of 
PGE2, BMcMCs were stimulated with PGE2 alone or together with anti-IgE. The above 
signaling protein molecules were analyzed regarding phosphorylation in cell lysates. 
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PGE2 in combination with anti-IgE inhibited the phosphorylation of PLCγ1 in a dose 
response manner in BL/6-MCs (Fig. 25) but not in Balb/c-MCs (Fig. 26). The 
expression of PLCγ2 was low in both strains and was not influenced by PGE2 (data not 
shown). ERK1/2 phosphorylation triggered via FcεRI was decreased (Figs. 25/26) in 
both strains. Conversely, PGE2 had no effect on p38 (Fig. 25) or JNK (data not shown) 
in BL/6-MCs, while a trend to an inhibitory activity was identified in Balb/c (Fig. 25). 
The phosphorylation of AKT, a downstream target and proxy of PI3K activation was 
found be reduced in Balb/c mice, while less activity was found in cells from BL/6 (Figs. 
25/26). 
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Figure 25: Anti-IgE mediated phosphorylation of PLCγ1 and ERK 1/2 was reduced in C57BL/6J 
mice. Sensitized BMcMCs were pre-incubated with different concentrations of PGE2 followed by 
stimulation with anti-IgE. A) Western blot analysis showing the expression/phosphorylation of mentioned 
proteins and cyclophilin (as a loading control). B-E) Band intensities obtained by scanning the blots in 
independent experiments, normalized to cyclophilin B. F-I, Band intensities as in B-E but given as a ratio 
of stimulated/unstimulated to determine the relative intensities presented under each blot. The data are 
presented as mean ± SEM, n=5-7 per group. *P< 0.05 and **P<0.01. 
Figure 26: Anti-IgE-mediated phosphorylation of ERK 1/2 and AKT was reduced in Balb/c mice. 
Sensitized BMcMCs were pre-incubated with different concentrations of PGE2, followed by stimulation 
with anti-IgE. A) Western blot analysis showing the expression/phosphorylation of mentioned proteins 
and cyclophilin (as a loading control). B-E) Band intensities obtained by scanning the blots in 
independent experiments, normalized to cyclophilin B. F-I, Band intensities as in B-E but given as a ratio 
of stimulated/unstimulated to determine the relative intensities presented under each blot. The data are 
presented as mean ± SEM, n=5-7 per group. *P< 0.05. 
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6.3.5 PGE2 has a donor-dependent impact on human 
mast cell activation 
PGE2 displays opposing effects on MC activation in cells from different mouse strains. 
This raised the question whether this phenomenon can also be replicated in human 
MCs. We used MCs isolated from breast skin of various donors (HuMCs) and 
performed histamine release assays. HuMCs were treated with various concentrations 
of PGE2, prior to MC activation and histamine release was analyzed in cell 
supernatants to measure cell activation. Treatment with PGE2 prior to FcɛRI 
aggregation showed that human MC responses varied across donors both in terms of 
direction and dose-response pattern replicating findings in the mouse (Fig. 27). These 
results suggest that the impact of PGE2 on human MCs and therefore ANA proneness 
might be influenced by genetic/epigenetic variation. 
 
 
 
 
 
 
 
 
 
 
Figure 27: PGE2 modulates HuMC activation in a donor-dependent fashion. HuMCs were 
sensitized overnight and pre-incubated with different concentrations of PGE2. MCs were stimulated and 
histamine release was quantified by an autoanalyzer-based method. The net release was determined 
in the following way ‘Net release= [stimulated release- spontaneous release] in %total. The data are 
shown as line graphs where each line corresponds to one donor, n=7. 
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6.3.6 EP receptor expression profile in mast cells 
The impact of PGE2 in MCs depends on the expression and function of the EP 
receptors. We analyzed the relative expression of EP receptors 2-4 in HuMCs. HuMCs 
exhibited prominent expression of EP4, followed by EP3 and EP2 suggesting the 
significance of EP4 receptor in MCs. These results also mimic the pattern in murine 
cells (Fig. 28). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: EP receptor expression profile in HuMCs. EP receptor expression in HuMCs was 
assessed via Real time PCR and normalized to the expression of HPRT. n=6. 
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6.3.7 Impact of EP agonists on human mast cell 
activation is donor-dependent 
To address the function of EP receptors, MCs were also treated with different doses 
of EP agonists 2-4, before MC activation was induced. Replacing PGE2 with EP-
selective agonists revealed that the EP2 agonist attenuated MC releasability in a 
consistent manner (Fig. 29A), while EP3 was stimulatory throughout in the experiments 
(Fig. 29B). Responsiveness to the EP4 agonist was variable (Fig. 29C), and 2 
response patterns were observed: one group displaying elevated and the other group 
showing decreased degranulation (Fig. 29D). Thus, PGE2 impacts human skin MC 
activation in a donor-dependent fashion caused by a variability of EP2/3/4 signal 
direction and strength across the population, where EP4 seems to be the most relevant 
receptor.  
 
 
 
 
 
 
 
 
 
 
 
Figure 29: The impact of EP agonists on HuMCs is donor-dependent. HuMCs were sensitized and 
pre-treated with different EP agonists 2-4. MCs were stimulated with anti-human IgE and histamine 
release was quantified by an autoanalyzer-based method. The net release was determined in the 
following way ‘Net release= [stimulated release – spontaneous release] in %total. n=9-10. *P< 0.05. 
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7. DISCUSSION 
 
PGE2 is an essential homeostatic factor with an emerging role in the regulation of 
immune functions.(144, 147, 221, 222) Dysregulated PGE2 has been associated with a wide 
range of pathological conditions.(223, 224) Studies in the last few decades have reported 
the aggravation of allergy and hypersensitivity by COX-inhibitors (NSAIDs). (135, 161-166) 
An imbalance of PGE2 is believed to be the main cause of NSAID-induced 
hypersensitivity disorders but it is still not clear. This hypothesis is supported by the 
clinical benefits of PGE2 (and synthetic analogues) in patients of airway 
hyperresponsiveness. (175, 176, 225, 226) Other evidence (173, 174) taken together with data 
from the European ANA registry (4) also suggest that PGE2 has a crucial role in allergic 
responses. The underlying mechanisms of NSAID-mediated hypersensitivity and the 
deregulations of the PGE2 system despite some pioneering attempts are still not 
understood completely. 
The aim of this thesis was to better understand the role of human and murine PGE2 in 
anaphylactic responses and study the underlying mechanisms. In addition, the 
influence of genetic variation on the PGE2 system was examined.  
The present data show that PGE2 deficiency causes susceptibility towards ANA and 
the pharmacological stabilization of PGE2 may protect against it. This thesis 
demonstrates that susceptibility to ANA is caused by MC hyperresponsiveness in the 
absence of homeostatic levels of PGE2. Moreover, genetic variation is an important 
factor influencing the impact of PGE2 on anaphylactic responses.  
 
7.1 PGE2 deficiency pre-disposes to anaphylaxis 
while its stabilization reduces the severity 
The intake of COX-inhibitors (NSAIDs) is associated with pro-anaphylactic effects in 
patients at risk. (124, 167, 173, 227) PGE2 is a pluripotent prostanoid which has been shown 
to regulate multiple facets of inflammation and functions of different immune cells such 
as mast cells. (228) It was hypothesized that a deficiency of PGE2 resulting from COX-
inhibition causes the pre-disposition towards ANA. This hypothesis was supported by 
studies showing a protective effect of PGE2 in allergic disease, (156, 167, 216, 229) combined 
 
78 
with differences in PGE2 abundance in allergic lung disease.(171, 229) Moreover, 
aggravation of rhinitis or asthma by ASA (COX-inhibitor) is attributed to a lack of PGE2 
secondary to COX-mediated reduction. (159, 170, 172, 230)  
Patients with a history of ANA were compared to healthy subjects regarding the levels 
of systemic PGE2. It was identified that ANA patients display reduced levels of serum 
PGE2 compared to healthy subjects. This finding was consistent with Higashi et al. who 
showed lower levels of baseline PGE2 in aspirin-intolerant asthma (AIA) patients as 
compared to the aspirin-tolerant asthma (ATA) group.(171) In addition, nasal polyps and 
airway fibroblasts isolated from patients of AIA were shown to have impaired 
production of PGE2. (170, 172, 216) Stratification of patients by severity grades, showed a 
negative correlation between serum PGE2 levels and the severity of anaphylactic 
reaction within the patient group. However, other biomolecules and MC mediators 
(such as histamine, tryptase, Cys-LTs and 9α,11β-PGF2) measured on the same 
serum samples in connection with our report on biomarker exploration to diagnose 
ANA, yielded no or minor differences only. (231) These findings together with our data 
indicate that PGE2 is reduced in individuals at risk to develop ANA and lack of 
homeostatic PGE2 might cause susceptibility towards ANA.   
In support of the clinical observations, a multitude of animal models of allergic diseases 
have shown a protective role of PGE2 in the elicitation of allergy. (135, 164-166) To confirm 
the hyposthesis, two mouse strains frequently used in allergy research (Balb/c and 
BL/6), were compared regarding their basal serum PGE2 levels and severity of ANA. 
BL/6 mice developed more severe ANA and possessed significantly lower PGE2 levels 
as compared to Balb/c. As in humans, PGE2 levels were inversely related to ANA 
severity between the two strains. This data is consistent with previous reports which 
showed that mice lacking PGE2 formation due to COX-inhibition or lack of the synthase 
enzyme gene display increased allergic inflammation. (134, 178) 
The presented data strongly indicates that the reduced levels of PGE2 might cause 
greater severity of ANA. To further confirm these results, stabilization of PGE2 was 
tested and the severity of ANA induced thereafter was analyzed. The rate of PGE2 
degradation is controlled by 15-PGDH enzyme which is responsible for converting it to 
inactive 15-keto-PGE2. (228, 232-234) Treatment with a selective 15-PGDH inhibitor (15-
PGDH-I), SW033291 in the PSA model increased systemic PGE2 and also showed a 
reduction in the severity of ANA in BL/6 mice. The use of SW033291 has been shown 
to significantly increase PGE2 levels in mice.(235) Consistent with these results, 
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immunologically naïve mice lacking 15-PGDH, showed reduced bronchoconstriction in 
response to methacholine.(236) Similarly, mice with increased PGE2 levels due to 
overexpression of PGE2 synthase in the lung showed reduced airway constriction. (236) 
This finding confirms that the reduced PGE2 levels are responsible for a greater 
anaphylactic severity. The pharmacological stabilization of PGE2 may be a novel 
approach to protect against ANA but is however determined by the given genetic 
background (section 7.3). 
 
7.2 Acetyl salicylic acid aggravates anaphylaxis 
while PGE2 protects against it 
A strong link between COX-inhibition and the onset of allergic symptoms comes from 
data about ASA-induced hypersensitivity upon the uptake of ASA/NSAIDs.(161-163) To 
further confirm the protective effect of PGE2, ASA-induced aggravation of ANA was 
studied using a PSA mouse model. In vivo treatment with ASA confirmed the 
exacerbation of ANA replicating the clinical situation in affected patients. However, 
provision of exogenous PGE2 completely protected against the pro-anaphylactic effect 
of ASA. This finding is consistent with the study showing that PGE2-deficient mice 
developed ASA sensitivity after induction of allergic airway inflammation.(237) 
Exogenous PGE2 is also known to inhibit ASA-induced bronchoconstriction in humans 
sensitive to these challenges (225, 226) but no such direct studies are reported in mouse 
models. 
Importantly, not only exogenous PGE2 was able to reduce ANA severity, the 
stabilization of endogenous PGE2 by means of 15-PGDH-I was likewise effective at 
attenuating ANA severity. These results are in agreement with Hartney et. al who 
showed a reduction of airway responsiveness in 15-PGDH knock out mice (Hpgd -/-) 
and PGE2 synthase overexpressed mice with increased PGE2 levels.(236) Lesser 
potency of the endogenous route can be explained by the lower amount of PGE2 
available for stabilization (especially after COX inhibition). The two approaches 
together, validate that the deficiency of the prostanoid underlies ANA aggravation after 
ASA intake. 
Based on the literature, COX-1 is the dominant enzyme providing protection from overt 
allergic responses. (134, 136, 238) The mechanism is also likely in the PSA model of ANA, 
which is induced in the absence of inflammation or infection. In vivo, COX-1 and COX-
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2 inhibitors were both able to exacerbate the anaphylactic reaction over basal level, 
thereby mimicking ASA. These results confirm that the ANA-promoting effect of ASA 
results from the inhibition of COX activity.(239-242) While SC-560 (COX-1 inhibitor) is 
reasonably selective (IC50 9 nM for COX-1 and 6,300 nM for COX-2), celecoxib (COX-
2 inhibitor) is less selective for its primary target (IC50 40 nM for COX-2 and 1,500 nM 
COX-1). The results suggest that the COX-2 inhibitor used is insufficient to differentiate 
between the functions of the two isoforms. Maybe, a more specific inhibitor such as 
valdecoxib (IC50 5 nM for COX-2 and 140 µM for COX-1) is more suitable due to its 
high COX-2 specificity. Another approach would be the use of COX-knockout mice 
which are already under generation for future studies. 
PGE2 acts through EP receptors 1-4, where EP2, EP3 and EP4 are the principal 
entities due to their broad expression in the body (214, 215) and their potential to exhibit 
distinct actions in the context of allergy and asthma. (156, 216) Treatment with selective 
EP agonists (166, 217-220) in the PSA model, showed that all three prostanoid receptors, 
EP2, EP3 and EP4 were able to reverse ANA-aggravation by ASA further emphasizing 
the significance of lacking PGE2 for increased ANA severity. EP2 agonist was more 
potent, possibly due to its efficient functional coupling to the cAMP pathway despite its 
lower expression. (216) In line with this finding, EP2 receptor agonist was shown to block 
airway resistance caused by lysine-aspirin treatment in mice.(237) Similarly, Zaslona et. 
al showed exaggerated airway inflammation in EP2 knock out mice subjected to OVA 
sensitization and acute airway challenge.(155) Exogenous EP2 stimulation has also 
been shown to prevent airway hyperresponsiveness and inflammation in mice.(243) 
Herrerias et. al showed EP2 to be overexpressed in house dust mite (HDM)-sensitized 
mice. This may reflect a compensatory strategy to counteract disease progression. (244) 
Moreover, in line with our results, EP4 agonist was reported to reduce OVA-induced 
airway inflammation in a mouse model. (245) 
While the results with EP2 and EP4 agonists are expected due to their direct protective 
effect on MCs in our in vitro study, EP3 agonist showed unexpected results since it 
has a potentiating effect on MCs. Even though EP3 has been viewed as an aggravator 
of allergy, Kunikata et al.(166) and Ueta et al.(246) reported that EP3 knockout mice 
developed more susceptibility to disease in experimental models of allergic asthma 
and conjunctivitis. Since the effect of EP3 could not be explained through direct MC 
attenuating function, EP knockout mice will be used in the future to verify these results 
and delineate the underlying mechanism. 
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Overall, these data show that the deficiency of PGE2 in both humans and mice causes 
a pre-disposition to ANA or aggravation of ANA by COX-inhibitors/ASA. PGE2 acts via 
EP receptors 2-4 to reduce anaphylactic responses and maintain its homeostatic 
function. Moreover, severe ANA could be protected by pharmacological stabilization 
of PGE2. 
 
7.3 Genetic variation influences the impact of PGE2 
on anaphylactic responses 
Strain dependence in the proneness to develop ANA is known.(62) Reports show 
differences in the anaphylactic responses of different strains of mice as disease 
models. (247-250) To study if differential ANA sensitivities result from genetic differences 
in the PGE2 network, two mouse strains, Balb/c and BL/6, typically employed in studies 
of allergic diseases were compared. These mice showed variations in their baseline 
levels of PGE2 and severity of systemic ANA. BL/6 mice displayed significantly lower 
serum PGE2 levels and developed a profoundly intensified ANA in contrast to their 
Balb/c counterparts. In line with these findings, Collins et. al showed that BL/6 mice 
developed stronger inflammatory response in comparison to Balb/c mice upon airway 
challenge. (251) These findings indicate that the PGE2 system and hence ANA severity 
is influenced by genetic variation at least when comparing these two strains. 
To increase the systemic availability of PGE2, a stabilizing 15-PGDH inhibitor was 
administered in both mouse strains. Treatment with the inhibitor increased serum 
levels of basal PGE2 in BL/6 mice but had no influence in Balb/c mice. This indicates 
that the activity or expression of 15-PGDH might be low in Balb/c mice and not 
responsive to inhibition. The suppression of 15-PGDH activity is reported in many 
forms of cancer to maintain high levels of PGE2.(252-255) Since Balb/c mice display 
tremendous amounts of PGE2, suppression of enzyme activity might be a possible 
reason. Genetic polymorphisms which could lead to differential expression and genetic 
variability are known in the human 15-PGDH enzyme gene (256) and might also be a 
possibility in Balb/c mice. However, this would need confirmation from further studies 
but hints at possibly different PGE2 metabolism in Balb/c mice. 
Increase in PGE2 levels by the inhibitor in BL/6 mice, reduced the severity of ANA and 
led to quicker recovery. In contrast, the effect of 15-PGDH-I in Balb/c mice could not 
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be determined. Strain dependent differences in the protective effect of a PGE2 receptor 
agonist are reported in mice.(164, 166) These results indicate a possible heterogeneity in 
the responsiveness of these strains towards PGE2. However, more animals are 
required to confirm these results. 
These data imply that results obtained for a single genetic background must be viewed 
critically and extrapolation to the entire population would be inadequate. Overall, these 
findings highlight that genetic factor may be an essential variable in the PGE2-MC-ANA 
connection and explain the conflicting reports about PGE2’s function in the literature. 
 
7.4  PGE2 protects against anaphylaxis by its direct 
impact on mast cells 
Mast cell activation is a central event in allergic inflammatory responses. MCs are 
potential targets for immunoregulation by PGE2.(153) PGE2 has emerged as an 
important mediator in studies of MC-related diseases. However, there is a lot of 
complexity/uncertainty associated with its role.(139, 257) Having found that PGE2 inhibits 
the aggravation of ANA in BL/6 mice, the impact of PGE2 on MCs from both strains 
was compared. PGE2 treatment induced opposing effects on anti-IgE mediated 
histamine release in MCs from both strains. While it increased MC stimulability in 
Balb/c, PGE2 reduced MC responsiveness in BL/6 mice. This contrast was also 
mirrored by a MC cytokine- TNF-α response. TNF-α release was inhibited in BL/6 mice 
but enhanced in Balb/c by PGE2 treatment. In the literature, PGE2 has shown variable 
and sometimes opposite effects on FcεRI-dependent MC degranulation. It has been 
shown to decrease the release of mediators like histamine, TNF-α and eicosanoids in 
rat peritoneal cells,(183) human MCs derived from cord blood(152), peripheral blood 
progenitors,(187, 190) or human lung MCs.(154)  On the contrary, other studies described 
PGE2 to exert a stimulatory effect on MC activation.(187-190) It is very important to note 
though, that the concentrations of PGE2 used in this study are much higher than in the 
literature to be consistent with the basal PGE2 concentrations measured in our mice. 
There were no differences however, between the two strains regarding other cytokines 
such as IL-6, IL-13, CCL-2 and CCL-3 (data not shown).   
Reasons for this dichotomy are complex. PGE2 can elicit different responses in MCs 
from different species,(151-153) different sites,(151, 152, 154) or even different donors.(189) 
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Increasing evidence (151-154, 188) links this paradox to the existence of four PGE2 
receptors, which are members of the GPCR family with partially opposite downstream 
pathways. (130, 143, 258) Their characteristic pattern of expression as well as their relative 
ratios vary across different cells and may explain the diverse PGE2 functions.(151-154, 
259) Analysis of the relative expression of the PGE2 receptors in BMcMCs revealed a 
comparably low expression of EP2 receptor and dominant expression of EP3 and EP4 
in both strains. However, EP3 receptor was significantly higher expressed in Balb/c 
mice.  EP receptor ratios were revealed as one reason of variation behind the effect of 
PGE2,(187) however, the focus was only on the relative expression of EP2 to EP3 on 
MCs. EP4 was shown to express at a low level and seemed to play a minor role due 
to its low presence. (260) This data presents evidence demonstrating the importance of 
the EP4 receptor. Brown et. al reported that EP4 is of biological significance only when 
EP2 is scarcely expressed in a given population.(191)  
To determine the specific EP receptor/s contributing to the impact of PGE2 on MCs, 
BMcMCs from both strains were treated with EP agonists alone and in combination. 
As expected, EP3 agonist increases histamine release in both strains. EP3 receptor 
has been reported to mediate potentiating effects of PGE2 on the degranulation and 
cytokine production of murine BMcMCs.(153, 188, 261) The higher expression of EP3 
receptor in MCs from Balb/c mice and the strong stimulatory effect of EP3 agonist 
explain the increasing impact of PGE2 in Balb/c-MCs. 
However, the activation of EP2 and EP4 receptor attenuated histamine release in BL/6-
MCs. In particular, EP4 was only effective at reducing MC activation in BL/6 MCs, but 
not in Balb/c-MCs. The suppressive effect of EP2 and EP4 agonists was more 
pronounced upon combination in MCs from BL/6. The combination reduced the 
response by 83% in BL/6 compared to only 36% in Balb/c thereby explaining the 
inhibition of MC response in BL/6-MCs by PGE2. In line with these results, a synergistic 
action of EP2/4 receptors has earlier been reported in other systems such as human 
aortic smooth muscle cells, where histamine responses were reduced by the activation 
of EP2 and EP4 receptors and in mouse airway smooth muscle, where cholinergic 
contraction was similarly reduced by both receptors.(262, 263) The involvement of the two 
receptors is evident by shared signaling pathways. EP2 and EP4 are both Gs-coupled 
receptors and act by increasing intracellular cAMP formation, although they also act 
through their individual alternative pathways.(148) Additionally, EP2 receptor has been 
 
84 
shown to suppress FcɛRI-dependent MC degranulation(187) and prevent airway 
hyperresponsiveness.(164, 243) Similar findings are reported for EP4 receptors.(264-266) 
Although, BMcMCs from BL/6 mice show high expression of EP3 receptor and a 
potentiating effect of the EP3 agonist, the combined inhibitory impact of the EP2 and 
4 receptors dominates the overall effect of PGE2. This may also be reasoned by the 
highest affinity of EP4 receptor for PGE2 among the EP receptors.(51) Overall, these 
results demonstrate that PGE2 can have diverse effects not only across MC subsets 
(187), but even within the same MC category, governed by genetic variation. Since the 
receptor expression was largely comparable between the strains, this data suggests a 
genetic influence on the signaling pathway employed by PGE2 in the two strains. 
IgER (IgE receptor) aggregation on MCs leads to a cascade of tyrosine kinase-initiated 
events that ultimately lead to the degranulation of MCs by direct or PI3K-mediated 
PLCγ activation. (62, 73) To investigate the opposing impact of PGE2 on the release of 
MC mediators (histamine and cytokines), key signaling events involved in the IgER-
mediated degranulation pathway were examined in both mouse strains. As expected, 
IgER cross-linking led to an increase in the phosphorylation of PLCγ1 and AKT 
proteins in both Balb/c and BL/6. However, PGE2 dose-dependently reduced IgER-
mediated phosphorylation of PLCγ1 and PI3K (assessed by the phosphorylation of 
AKT, a surrogate marker for the activation of PI3K) in BL/6-MCs. The expression of 
PLCγ2, however, was found to be low and the phosphorylation was not detectable 
although both isoforms have been detected in MCs in the past.(267) PI3K has been 
shown to have a role in PLCγ activation leading to Ca+2 mobilization and degranulation 
(268). In line with these results, PGE2 treatment reduced PLCγ phosphorylation in 
alveolar macrophages infected with Histoplasma.(269) These findings indicate that the 
PGE2-mediated attenuation of MC degranulation in BL/6-MCs takes place through 
suppression of PLCγ1 and AKT phosphorylation. However, the role of PI3K in PLCγ 
phosphorylation should be confirmed by using PI3K inhibitors in the future.  
Cytokine gene transcription is regulated by the activation of mitogen activated protein 
kinases (MAPKs; ERKs, c-Jun N-terminal kinases (JNKs), and p38 MAPKs), in MCs. 
(270, 271) MAPK pathways co-ordinate with each other to regulate TNF-α expression. (272) 
IgER-mediated phosphorylation of ERK 1/2 likewise, was reduced by PGE2 in BL/6-
MCs potentially explaining the reduction in TNF-α production. Inhibition of ERK 
activation was reported to impair TNF-α production in monocytes.(273) Despite the trend 
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to increase basal ERK phosphorylation in PGE2 treated cells the effect was not 
significant at any concentration (data not shown). In contrast to ERK 1/2, no impact of 
PGE2 on the IgER mediated phosphorylation of p38 and JNK (data not shown) was 
found. This data is in accordance with studies showing that PGE2 can prevent the 
activation of NF-κB and MAP kinases, thereby inhibiting the transcription of pro-
inflammatory cytokines.(266, 274) These data indicate that ERK ½ is the only MAPK 
affected by PGE2 to downregulate TNF-α production in BL/6-MCs. 
However, in Balb/c-MCs, PGE2 suppresses the phosphorylation of AKT and ERK 1/2 
but has no impact on PLCγ1 phosphorylation. These findings indicate the involvement 
of other players in the potentiation of degranulation and TNF-α release in Balb/c. In 
agreement with these results, PGE2 was shown to impair calcium responses, ERK and 
AKT phosphorylation through activation of EP3 receptors in rat astrocytes.(275) Data 
from the EP agonist and MC activation experiments indicate the possible role of EP3 
receptor in Balb/c-MCs. EP3 receptor was reported to potentiate IgER-mediated 
degranulation and cytokine production by utilizing a PI3K-independent integration 
pathway in MCs. This pathway involves the synergistic activation of PLCγ and β. (276) 
Therefore, in order to find the mechanism underlying the enhancement of 
degranulation in Balb/c-MCs, the involvement of PLCβ or calcium mobilization should 
be studied in the future. 
With insights of opposing responses to PGE2 in MCs from different mice strains, we 
asked whether genetic variation also influences PGE2 responses in HuMCs. The 
impact of PGE2 in HuMCs varied across human donors both in terms of direction and 
dose-response. To find out if the relative EP receptor 2-4 expression varied among 
donors, an analysis of the EP receptor expression was performed. Various donors 
showed a consistent pattern of EP receptor expression with high expression of the EP4 
receptor. Moreover, treatment with selective EP agonists showed a consistent 
reduction in MC release by EP2 agonist throughout the population, while EP3 agonist 
overall potentiated the release of histamine. Interestingly, donors displayed mixed 
responses towards the EP4 agonist. High expression of the EP4 receptor and varied 
MC responses towards EP4 agonist among donors suggest a potential role of this 
receptor. These data also suggest a protective effect of the EP2 receptor, but its 
expression is low in these MCs. In the literature, EP4 receptor is known to reduce 
inflammatory and allergic responses.(277-279) A report published by Gilfillan et al. (189) 
showed that different PGE2-responder and non-responder populations exhibit 
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heterogeneity in their responsiveness to PGE2 due to differences on a molecular level. 
Therefore, studies involving the EP4 gene or molecular players like PLCγ, ERK 1/2 
should be performed to pinpoint differences in the PGE2 system between donors. 
Collectively, these data suggest that the impact of PGE2 on ANA results from its direct 
impact on MC activity through the EP receptors. Our direct comparison of mouse 
strains and human donors reveal the importance of EP2 and EP4 receptors as 
opposed to only EP2 receptor in the literature. Clearly, further studies using EP 
knockout mice would help to delve deeper into the role of the three EP receptors and 
their downstream components in the impact of PGE2 on MCs and therefore ANA. 
 
7.5 Conclusion and Outlook 
This thesis investigated whether and how an impaired PGE2 system is associated with 
ANA susceptibility and influenced by genetic background of the host.  
The results presented provide new insights into the interplay between COX-PGE2-
MCs-ANA.The data shown revealed that ANA patients and ANA-prone C57BL/6 mice 
are characterized by reduced levels of PGE2. Since PGE2 levels correlated inversely 
with the severity of anaphylactic reaction, these results indicate that a lack of PGE2 
contributes to ANA susceptibility. Moreover, differential PGE2 levels between mouse 
genotypes contribute to differential ANA-susceptibility. BL/6 mice showed better 
sensitivity towards allergen-induced ANA than Balb/c mice and would prove to be a 
better model for future studies of ANA. The molecular mechanisms for the lack of PGE2 
in ANA patients are incompletely understood and will be studied on the genomic level. 
Stabilization of PGE2 by inhibiting its degradation or administration of exogenous PGE2 
protects BL/6 mice against ANA and the exacerbation of ANA by ASA. These results 
confirm that the relative lack of PGE2 increases the risk or severity of ANA. PGE2 
stabilization may be used to develop a possible therapeutic approach for the 
management of ANA. However, stabilization of PGE2 could not be achieved in Balb/c 
mice indicating possible differences in PGE2 regulation between the two strains. To 
get a better understanding of the PGE2 system in Balb/c mice, the activity and 
expression of the 15-PGDH enzyme should be studied in the future. 
To confirm the protective role of PGE2 in vivo, aggravation of ANA by ASA was studied. 
ASA worsens ANA through COX-1 and COX-2 inhibition validating the importance of 
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COX. PGE2 protects mice against the pro-anaphylactic effect of ASA through its EP 
receptors 2-4. However, to identify the specific enzyme subset responsible for the 
protective effects of COX during elicitation of ANA, a more selective inhibitor of COX-
2 (such as valdecoxib), in addition to COX-1 and COX-2-deficient mice will be used in 
the future. 
To delineate the mechanism of PGE2-mediated protection from ANA, the impact of 
PGE2 on MC responsiveness was studied. MCs from Balb/c and BL/6 mice exhibit 
heterogeneity in their responsiveness towards PGE2 signifying the importance of 
genetic background. Using selective EP agonists, it was observed that exogenous 
PGE2 reduces MC stimulability in BL/6 mice through EP2 and EP4 receptors. However, 
in Balb/c mice, MC responses are potentiated through the EP3 receptor. PGE2 
develops its protective effect through EP receptors 2 and 4 by direct impact on MCs 
and by EP3 receptor (in vivo) by a mechanism located upstream of MC degranulation. 
Collectively, all three EP receptors are involved in ANA responses and act to prevent 
ANA even though the EP3 receptors act in an opposite way on MCs. These results 
confirm that homeostatic levels of PGE2 attenuate MC responses through EP receptors 
2-4 and reduce ANA susceptibility. The EP3 receptor and the protective impact of the 
EP receptors in ANA will be studied in more detail using EP knockout mice in the future.  
To better understand the heterogeneity in MC responses towards PGE2 in the two 
genotypes, MC signaling cascade was studied. PGE2 reduces MC responses in BL/6 
mice by interfering with the phosphorylation of key signaling molecules- PLCγ1 and 
ERK 1/2. However, the molecular players involved in PGE2-mediated increase of MC 
responses in Balb/c could not be determined. Since the data highlights a possible role 
of the EP3 receptor, signaling intermediates downstream EP3 receptor such as PLCβ 
or calcium mobilization should be studied in Balb/c mice in the future.  
To study if PGE2 has a protective impact on human MCs, cells from various donors 
were treated with exogenous PGE2.The impact of PGE2 on MC activation varies across 
donors and was supported by variability in responses towards EP 2/3/4 agonists most 
importantly EP4. Moreover, HuMCs show dominant expression of the EP4 receptor. 
Together, these results underline the influence of genetic variation on the PGE2 system 
and MC responses. The significance of individual EP receptors in the human PGE2 
network will be studied in detail by knockdown. 
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The PGE2 system is complex with diversity at distinct levels comprising PGE2 
synthesis, transport, degradation and function (by differential expression or coupling 
of EP receptors). Genetic studies of the PGE2 system in humans and mice and studies 
using EP knock out mice or EP knockdown in human MCs can be used to gain deeper 
insights into the intricate PGE2 network. 
To conclude, this thesis reveals an important role of homeostatic PGE2 and its EP 
receptors 2-4 in the moderation of ANA susceptibility through direct impact on MCs. In 
addition, it shows genetic background as an important factor influencing the PGE2 
system and ANA susceptibility. It highlights the potential use of PGDH-inhibitors in 
therapeutic or preventive strategies for ANA management. 
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